Known pathogenic gene variants and new candidates detected in Sudden Unexpected Infant Death (SUID) using Whole Genome Sequencing (WGS)

Angela M. Bard[1], Lindsay V. Clark[6], Erdal Cosgun[6, 7, 8], Kimberly A. Aldinger[1, 3, 4], Andrew Timms[5, 6], Lely A. Quina[1], Juan M. Lavista Ferres[6, 7, 8], David Jardine[3], Elisabeth A. Haas[9], Tatiana M Becker[1], Chelsea M Pagan[1], Avni Santani[10], Diego Martinez[10], Soumitra Barua[10], Zakkary McNutt[10], Addie Nesbitt[10], Jan-Marino Ramirez[1, 2, 3]

[1]Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA; [2]Department of Neurological Surgery, [3]Department of Pediatrics, and [4]Department of Neurology, University of Washington School of Medicine, Seattle WA, [5]Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA; [6]Bioinformatics and Research Scientific Computing, Seattle Children's Research Institute, Seattle WA; [7]AI for Good Research Lab, Microsoft, Redmond WA; [8]Microsoft Genomics Team, Redmond WA; [9]Department of Research, Rady Children's Hospital-San Diego, San Diego, CA. [10]Let's Get Checked, Monrovia, CA

Abstract

Purpose: In this study we performed WGS of children that succumbed to SUID during their first year of life to gain insights into potential genetic risk factors that could contribute to an infant's vulnerability to this tragic outcome.

Methods: Whole genome sequencing was performed on 145 SUID cases, and 576 healthy adult controls. Variants were filtered by gnomAD allele frequencies and predictions of functional consequences using computational tools.

Results: In 63.4% of our cohort, we identified 156 variants of interest in 86 genes, including 128 rare/ultra-rare variants in 71 genes that were previously associated with SIDS/SUID/SUDP. Eighty-eight variants were found in 43 genes that can be characterized as cardiac genes, and have previously been associated with cardiomyopathies, Brugada and Long QT syndromes, among others. Twenty-nine variants were also found in 22 genes previously reported in SIDS/SUID/SUDP that are related to neurologic function. Nineteen variants were found in 13 genes that are reported to be pathogenic for various systemic disorders, 11 of which occurred in six genes that have been previously described in SIDS/SUID/SUDP and eight that have not. We also identified 20 variants in eight genes implicated in the response to hypoxia and the regulation of reactive oxygen species (ROS) not previously described in SIDS/SUID/SUDP.

Conclusion: Our study confirms and further expands the list of genetic variants associated with SUID. The abundance of genes associated with heart disease and the discovery of variants associated with the redox metabolism has important mechanistic implications for the pathophysiology of SUID.

Keywords: Sudden Infant Death Syndrome, Sudden unexpected infant death, Sudden unexplained infant death, ROS, cardiomyopathy, *AAGAB, ABCC9, ACTN2, AKAP10, AKAP9, ALB, ANK2, ATM, BAG3, BRCA1, C12orf65/MTRFR, CACNA1C, CACNA1H, CACNB2, CACNB4, CALM2, CFTR, CHD2, CHRNA1, CLCN4, COL7A1, CTNNA3, DCHS1, DNM1L, DPP6, DSG2, DSP, DYNC1H1, DYRK1A, EFHC1, FLNA, FLNC, FPGT-TNNI3K, GJA1, GPR98/ADGRV1, GRIN1, GRIN2A, GRIN2B, HBA2, HCN4, ITGB3, JPH2, KCNA2, KCND2, KCNH2, KCNMA1, KCNQ3, KCNT1, LAMA4, LAMB3, LDB3, MYBPC3, MYH11, MYH6, MYLK, MYPN, NOTCH1, PHOX2B, PIEZO2, POLG, PRDM16, RANBP2, RANGRF, SLC25A35, RYR2, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN3B, SCN4A, SCN5A, SCN8A, SCN9A, SLC2A1, SLMAP, SMAD3, SPG7, TBX5, TGFB3, TMEM43, TNNC1, TRDN, TRPM4, TSC1, TTN*

Introduction

Sudden Infant Death Syndrome (SIDS) is defined as the sudden and unexpected death of an infant younger than one year, for which the cause of death remains unexplained despite a thorough investigation including a complete autopsy, and review of the circumstances of death along with review of the clinical history (1). The term SUID or sudden unexpected infant death (SUID) is more encompassing. Using the *International Classification of Diseases, 10th Revision* (ICD-10), both the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) define SUID as a larger category that encompasses three types of infant death in children prior to 1 year of age: "sudden infant death syndrome (SIDS; R95), deaths from other ill-defined or unknown causes (R99), and accidental suffocation and strangulation in bed (W75)" (2). SUID remains a significant public health problem. One of the leading causes of infant mortality, it is estimated that SUID contributes to the deaths of approximately 3,400 infants in the United States each year (3).

Many risk factors have been identified for SIDS/SUID including ethnicity (3), prematurity (4), maternal smoking during pregnancy (4, 5), lower birth weight (4), bed-sharing (4), prone sleeping (6, 7), recent infection (8), geographic variations (9), and environmental exposures such as air pollution (10). The recognition of prone sleeping as a major risk factor led to the adoption of safe sleep practices which was associated with significant reductions in SUID rates in the 1990's and early 2000's. Increased educational efforts (11) could further increase the adherence to safe sleep practices, and also

reduce the incidence of maternal smoking, which in turn could decrease the number of SUID deaths. Unfortunately, despite increased educational efforts, SUID rates have plateaued since the early 2000's (3). Further deaths could also be prevented through the early recognition of a child that is at risk for SUID. Abnormalities in cardiorespiratory coupling, or in inflammatory responses could be recognized by devices that recognize early physiological warning signs. DNA sequencing is another potential strategy to identify a child that is at risk to succumb to SUID. DNA sequencing has already identified genes related to cardiac, neurologic, and metabolic disorders that could be linked to SUID (12-24). The early identification of high-risk genes could potentially also be important for preventing mortality and morbidity for children that survive beyond the one-year window for SUID. The identification of risk genes could also help in the diagnosis of a sudden death. Identifying a gene variant as the potential contributor to the fatal outcome could bring closure to surviving members of a family who lost a child for unknown reasons. With the aid of genetic counseling, parents could be better informed of risk of recurrence when considering expanding their families. Identifying genes associated with SUID can also yield important mechanistic insights into the general cause of SUID.

The triple risk model provides an important conceptual framework to assess how a potentially pathogenic gene variant could contribute to a fatal outcome (25). First proposed in 1972, but evolved over time, this concept puts forth the hypothesis that SUID occurs during a critical development period when a vulnerable infant is exposed to an extrinsic stressor (25, 26). A pathogenic gene variant could interfere with any of the three risk factors. It could increase or imbue a child with an intrinsic vulnerability, it could interfere with the response to a particular external stressor, and it could alter the normal developmental trajectory. Importantly, it is generally assumed that none of these isolated threats is significant enough to cause death alone, but when combined, the triple risks reach the threshold for a fatal outcome. Based on numerous neuropathological and neurophysiological studies it is hypothesized that the concurrence of the triple risk (developmental window of postnatal day 6-365, intrinsic vulnerability and external stressor) leads in most cases to failed arousal to external stressors associated with hypercapnic and/or hypoxic conditions (27-30). The conditions become fatal as the child suffers a terminal apnea event leading to severe irreversible hypoxic damage and ultimately cardiac arrest. However, there are also reports that a child can succumb to apnea, sudden cardiac arrest or perhaps a catastrophic immunological response that is not caused by a failed arousal. Risk genes associated with cardiac and neurologic disorders including cardiomyopathy and channelopathies or metabolic conditions such as fatty acid oxidation or glucose metabolism errors (12-24) could be potential candidates for such fatal events. While these considerations support the notion that a multitude of pathways can lead to SUID, there are certain features of SUID that are shared and are reproduced world-wide. These common features include male dominance (4), the characteristic age distribution which peaks at the second month and ends at one year of age (4) and maternal smoking (5) as well as prone sleeping (6).

Next-generation sequencing (NGS) studies have accelerated the study of a wide range of heritable diseases. In the present study we performed WGS of 145 children that succumbed to SUID. Our complete, non-targeted approach to sequencing confirmed variants in genes in which altered function have been previously implicated in SUID. We also discovered novel potentially pathogenic variants that are associated with the hypoxic response, the production of HIF1α and the regulation of reactive oxygen species (ROS).

Materials and Methods

1. Case/Control Acquisition

Postmortem tissue specimens from 145 de-identified children who died from SIDS/SUID were obtained from the NeuroBioBank (NBB) at the National Institute of Health (NIH), Seattle Children's Research Institute (SCRI) and the University of Washington (UW). The majority of tissue collected consisted of brain tissue (96.5%), but for some cases, only liver tissue or blood was available. Autopsy reports and partial medical history were available for 50 infants in the cohort. For the remainder of the cohort, limited data were provided. Autopsy findings along with the medical examiner's comments were reviewed when available. The circumstances of cases for which asphyxia was the stated cause of death were carefully examined and those that were a clear case of mechanical asphyxiation, rather than positional asphyxia, were excluded. Sequencing results (VCFs) from 576 healthy adult controls were obtained from Veritas (newly acquired by

Let's Get Checked). The control population ranged in age from 18 to 100+, with 47 (8.16%) over 100 years old (31). See Figure 1 for flowchart.

2. Whole Genome Sequencing

All case and control samples were subjected to a quality control assessment for high molecular weight DNA and degradation utilizing SNP chip and TapeStation prior to library construction (31). Samples that passed the quality assessment were processed with the TruSeq DNA PCR-free sample preparation kit and sequenced (31). Samples were sequenced to an average of approximately 30X coverage on the Illumina HiSeq X 10 or NovaSeq 6000 next generation sequencers (31). The paired-end sequencing protocol was used targeting an average read-length of 150 base pairs (31). Samples were required to meet or exceed 97% of bases > 10X coverage (31). Veritas performed primary analysis on the results which yielded two FASTQs per sample. Secondary analysis was also performed by Veritas using MicroSoft accelerated algorithms and yielded one BAM file and genomic variant call file (gVCF) per sample. Tertiary analysis was completed at Microsoft and SCRI. Joint genotype calling was performed with GATK GenotypeGVCFs.

3. Population Structure Analysis

To confirm a lack of major batch effects between cases and controls, population structure was visualized across the 721 individuals. The joint-called variant call file (VCF) was pruned with BCFtools (32) to only retain variants with less than 10% missing data, removing variants with linkage disequilibrium of 0.25 or greater with another variant, retaining a maximum of 10 variants per 100 kb. The variants were then imported into R and further filtered to only retain autosomal, biallelic variants with excess heterozygosity below 125 and an alternative allele frequency between 0.02 and 0.5, yielding 9252 variants. Principal components analysis, using the PPCA method from the pcaMethods Bioconductor package to handle missing data, was run on the genotype matrix (33). The first 50 axes were retained and used as input to UMAP (34) for visualization. Self-identified race and results from GrafPop (35) were used to determine the ancestry of each cluster (Figure 2).

4. Gene Level Analysis

4.1. Annotation and filtering

BCFtools (32), SnpEff (36), Slivar (37), ANNOVAR (38), and SnpSift (39) were used to add functional annotation, predictions of pathogenicity, gnomAD allele frequencies (40), and data from ClinVar (41) to the VCF. Variants were excluded if they were listed as Benign or Likely benign in ClinVar, if their inbreeding coefficient was below -0.4 or above 0.4, if their excess heterozygosity was above 125, or if the alternative allele frequency was greater than 0.05 within the dataset. To eliminate variants with dramatically different call rates between cases and controls, Fisher's exact test was performed for each variant on the contingency matrix of missing vs. called genotypes in cases and controls, and variants were excluded if the odds ratio was greater than 8 or less than 0.125 and the P-value was less than 0.01. An allele frequency cutoff for maximum frequency in gnomAD was set to 0.0001 for putative dominant variants, and 0.005 for putative recessive variants. Two allele frequency filters were then applied. (1) In the first filter, if a variant was homozygous in any individual, it had to pass the recessive allele frequency threshold in all populations. Other variants had to pass the dominant allele frequency threshold in all populations. This filter yielded 18,498 variants. (2) The second filter was the same as the first, except that variants had to be completely absent in the controls (unless they were homozygotes in the cases and only heterozygotes in the controls), yielding 2764 variants.

Three filters, decreasing in stringency, were then applied to these two filtered datasets. (1) The first filter retained only variants labeled as Pathogenic (P) or Likely pathogenic (LP) in ClinVar, yielding 120 variants across 102 genes out of the 18,498 variants in cases and controls, and 21 variants across 21 genes out of the 2764 variants only in cases. (2) The second filter included all variants from the first, plus any that were indicated as deleterious using three out of six computational methods, including MetaSVM, FATHMM or fathmm_MKL_coding, Polyphen2 HDIV or HVAR, CADD, GERP++, and DANN.

This filter yielded 3474 variants across 2673 genes out of the 18,498 variants in cases and controls, and 656 variants across 626 genes out of the 2764 variants only in cases. (3) The third filter included all variants from the first two plus any splicing, frameshift, or stop gain variants. This filter yielded 9764 variants across 5030 genes out of the 18,498 variants in cases and controls, and 1151 variants across 988 genes out of the 2764 variants only in cases.

4.2. Gene-level comparison of cases and controls

The three filtered sets of variants found across cases and controls (120 for ClinVar P/LP, 3474 for ClinVar P/LP or computational methods, and 9764 for ClinVar P/LP, computational methods, frameshifts, splicing, or stop gain) were used to test for genes in which variants were more frequent in cases than in controls. For each variant set, a gene-by-individual matrix was constructed, tallying the number of variants within each gene and individual. Variants that were homozygous in any individual were only counted in individuals in which they were homozygous. A baseline rate ratio was also calculated for each variant set as

$$R = \frac{V_{case}}{N_{case}} \Big/ \frac{V_{control}}{N_{control}}$$

where *V* is the sum of all observations of variants across all genes within the set, and *N* is the total number of genotype calls. For each gene with at least five observations of variants in a given variant set, a one-tailed Poisson test was then run to see if the rate ratio within that gene was higher than the baseline rate ratio. Multiple testing correction was performed across genes within each variant set using the False Discovery Rate (FDR) method of Benjamini and Hochberg (42). See Figures 3 and 4.

4.3. Gene ontology enrichment in cases vs. controls

A Poisson test similar to that used to detect significant genes was run on 13,774 gene ontology (GO) terms, using the sum of observation of variants across genes within each ontology term. Multiple testing correction was not appropriate given overlap among ontology terms, so instead a p-value cutoff of 0.00001 was used.

4.4. Gene ontology enrichment in cases only

Lists of genes in cases only for each of the three sets were analyzed in STRING-DB for protein – protein interactions and enrichment in GO terms (43). Genes from the three sets were analyzed using the full STRING network. The required score was set to the medium confidence level of 0.400 and FDR stringency was set to medium, 5%.

5. Variant Level Analysis: Gene Discovery Mendelian Pipeline

The control VCF was decomposed, subset and annotated with an Ensembl gene annotation using bcftools (32). Slivar was used to prioritize variants based on quality, coverage, allele balance and population frequency in gnomAD (37, 40). In addition, Slivar was used to add control counts and gene-based information for probability of being loss-of-function intolerant (pLI) score and any Online Mendelian Inheritance in Man (OMIM) associations (37, 44). Annovar was used to add additional variant-based annotation including: refGene model, ClinVar, CADD, GERP++, PolyPhen2 score and Geno2MP information (38).

Variants were prioritized using the following criteria: ≥10 reads; genotype quality ≥15; allele balance of >0.8 for homozygous alternate and between 0.2 and 0.8 for heterozygous; max gnomAD population frequency of ≤1%, and were determined to be functional (including missense, frameshift, or splicing [splice acceptor, splice donor or splice region i.e. within 8bp of a exon]). Variants that appeared in controls were excluded.

Included here are variants only described as rare/ultra-rare (<0.005%) in gnomAD, with noted exceptions, associated with autosomal dominant (AD) conditions, though some variants are also associated with multiple conditions including those of autosomal recessive (AR) inheritance. Infants were all heterozygous for the variant unless otherwise stated. When a variant is associated with AR conditions alone, it is only included if the infant had two variant alleles for that gene in different phases. The allele frequency of these variants is reported specific to the ethnicity of the infant. When the

ethnicity of the infant was not available, the total allele frequency for the combined ethnic groups in gnomAD is reported (20).

RESULTS

1. Cohort Characteristics (Table 1)

1.1. Demographics

Ethnicity and biological sex information for the participants was obtained along with the NIH samples according to their protocols. For those infants that were enrolled in the study at Seattle Children's, this information was reported by the parent/s of the child and/or the medical examiner (ME) at the time of autopsy. Our study cohort was split primarily between those of Northern European (NE) (50.34%) and African (A) (43.45%) ancestry. A small percentage of individuals were of Hispanic (Hisp) origin (2.07%) and American Indian (AI) heritage (1.38%). Also included in this study are four individuals for whom ancestry was not specified (2.76%). Most decedents were male (54.48%), with females comprising 45.52% of the study. The average age at death was 94.18 ± 4.68 days (SE); 62.76% of the cohort died between 60 and 180 days, 26.9% were less than 60, but greater than 7 days old at death, 8.28% of the cohort were greater than 180 but less than 365 days old. For three infants, 2.07% of the cohort, age at death was not available.

1.2. Gestational Age

Gestational age at birth was reported for 71 individuals (48.97%) in the cohort. Twelve infants (8.28%) were reported to be less than 34 weeks of age at birth. Sixteen infants (11.03%) were between 34 and 36 weeks of age at birth. Forty-three infants (29.66%) were greater than 37 weeks at birth. For 74 infants (51.03%) in the study, gestational age at birth was not reported.

1.3. Multiple Births

Eleven decedents (7.59%) in the study were the result of a multiple birth. Ten individuals were twins, and one was a triplet. Of these eleven infants, gestational age at birth for nine was reported. Two infants were greater than 37 weeks of age at birth. Four were between 34 and 36 weeks at birth, and three were less than 34 weeks of age at birth. None of the surviving siblings of these multiple births were reported to have any medical issues at the time of death.

1.4. Mild Illness

In addition, 36 decedents, 24.83% of the cohort, were reported to have had mild illness at or within one week of death. These illnesses, ranged from colic to encephalitis, but mostly included illnesses for which respiratory symptoms were the primary feature. However, these were determined not to be causative of their deaths.

1.5. Autopsy Findings and Medical History

Autopsies revealed changes in the lungs of twenty-seven decedents (18.62%) ranging from mild to moderate interstitial and vascular congestion (9.66%), evidence of chronic inflammation (3.45%), and some evidence of bacterial and/or viral infection (4.14%). One child had (0.69%) a collapsed lung and one child (0.69%) had structural differences in the lobes of their lungs, but these findings were not determined to be causative of death and some cases with congestion were reported to be due to intubation at the time of attempted resuscitation. A history of apnea or respiratory dysfunction was reported in nine individuals (6.21%), three of these infants are included in the count of twenty-seven with findings in the lungs at autopsy. One of these children had pulmonary congestion, one had bronchopulmonary dysplasia and one had structural differences in their lungs. There were no findings reported at autopsy for the remaining six individuals that had a history of apnea or breathing difficulties.

Thirteen decedents, 8.97% of the cohort, had cardiac findings at autopsy. Four decedents (2.76%) were reported to have heart defects determined not to be causative of death, two of which were heart murmurs, one an atrial septal defect and one unspecified defect. Nine infants (6.21%) had cardiac pathology findings at autopsy. Five of these had myocyte abnormalities, two had petechia found in the heart, one had myocardial contraction bands and pericardial effusions and one had focal intimal thickening in the right carotid artery. These findings were determined to be either incidental or of

unknown significance and not causative of death. An additional three infants (2.07%) were reported to have a history of cardiac complications, but these were not the infants with cardiac findings at autopsy and for two of these infants, these issues were thought to have resolved. The third infant was noted to have "infant tachycardia". It is unclear whether this had resolved.

Eight decedents, 5.52% of the cohort, had documented neuronal changes at autopsy including four (2.76%) with evidence of ischemic brain injury, one (0.69%) with reactive gliosis of the white matter, one (0.69%) with focal granule cell dispersion in the hippocampus, one (0.69%) with pontosubicular necrosis determined to be a nonspecific indicator of perinatal stress, and one (0.69%) with subdural and subarachnoid hemorrhage of unknown etiology. Three of the four individuals with evidence of ischemic brain injury were not found to have findings in their lungs at autopsy, nor did they have a reported history of respiration dysfunction.

Eight infants, 5.52%, were described with abnormalities in the kidneys ranging from congestion to evidence of kidney failure. Five infants (3.45%) were reported to have congested kidneys. One infant (0.69%) was described as having vacuolization and thickening walls of the small vessels. One infant (0.69%) was reported to have a single horse-shoe shaped kidney and an additional infant (0.69%) was described as having evidence of chronic inflammation, calcification, and renal failure. This infant was also reported with abnormalities in several organ systems including evidence of hypoxic ischemic injury.

Seven infants, 4.83% of the cohort, were determined to have endocrine conditions. All seven were identified as either having adrenal disorders and/or adrenal findings at autopsy. One of these infants was diagnosed with congenital adrenal hyperplasia and ambiguous genitalia, an additional two of these seven had elevated 17-hydroxyprogesterone (17-OHP), but with no histologic evidence of adrenal hyperplasia. One of these infants was also described as having a fatty liver. Another one of the seven was found to have adrenal hypoplasia, while the remaining three had congested adrenal glands at autopsy.

Seven infants (4.83%) had abnormalities in the liver at autopsy. Three (2.07%) were found to have congestion and two (1.38%) were described as having fatty livers. One infant (0.69%) was found to have both congestion and steatosis along with increased cellularity. An additional infant (0.69%) was noted to have evidence of chronic liver inflammation.

Six decedents, 4.14% of the cohort, were found to have abnormalities in the spleen at autopsy. Five of these had a congested spleen, one of which had the presence of sickled red blood cells. One of these six infants was found to have an enlarged spleen, but congestion was not noted.

Six infants (4.14%) had autopsy findings in the thymus gland. Four were found to have petechiae. One (0.69%) was described as having congestion, and one (0.69%) was noted to have a prominent thymus gland with cervical extensions and a cyst.

Four decedents, 2.07% of the cohort, were reported to have metabolic irregularities, including one with excessive glucose levels and A1C at autopsy, and one with previously diagnosed neonatal diabetes mellitus. Three of these decedents were the infants previously described as having fatty livers at autopsy.

1.6. Exposures

A total of ten infants, 6.90% of the cohort, were reported to have been exposed to substances such as cigarettes, alcohol and/or drugs such as benzodiazepines, cannabis, cocaine, methamphetamine, and/or opioids *in utero* or postnatally. Six of these children were exposed to multiple substances in various combinations. Five infants were exposed to opioids, including two that were reported to be opioid addicted at birth. Two of these were also exposed to alcohol, cigarettes, and other drugs. One was exposed to both opioids and cocaine, but not cigarettes or alcohol. Two of these five infants were exposed to opioids only. One additional infant (0.69%) was exposed to cocaine alone, and another (0.69%) to cannabis alone. Three children (2.07%) were exposed to alcohol and of these, all three were also exposed to cigarettes

and other drugs. Five children (3.45%) were reported to be exposed to cigarettes either *in utero* or postnatally. All five were also exposed to some combination of the previously mentioned drugs and/or alcohol. None of these ten infants had positive toxicology tests for these substances at autopsy, though in some instances their mother's continued to use them postnatally while breastfeeding. An additional two infants, 1.38%, had positive toxicology results that were determined to be unrelated to their deaths. One tested positive for diazepam and midazolam and the other, caffeine. The positive diazepam and midazolam results were determined to be related to the intubation at the time of attempted resuscitation, and the positive caffeine result was determined not to have contributed to the decedent's death.

1.7. Sleeping Circumstances

For 106 decedents (73.11%) at least one aspect of the sleeping circumstances was reported, which included the co-sleeping status. For 58 infants (40.00%), sleeping position was reported at the time of death. Forty infants (27.59%) were reported to be found in the prone position at time of death. Thirteen (8.97%) were reported to be supine and five (3.45%) infants were reported to be on their side when found. Position at time of death was not reported for 87 decedents (60.00%). Sixty-five (44.83%) were reported to be sleeping alone at the time of death. Forty-one infants (28.28%) were reported to be co-sleeping with either parents or siblings. For 39 individuals (26.90%), the co-sleeping status was not reported.

For approximately half of the cohort (49.66%), the sleeping surface was reported. Thirty-five infants (24.14%) were found on a bed or mattress. Fourteen infants (9.66%) were found in cribs. Seven infants (4.83%) were found in portable cribs or playpens. Four infants (2.76%) were sleeping in bassinettes at the time of death. Four (2.76%) infants were found on sofas. Three infants (2.07%) were being held by their mothers, either on their chests or laps when they were discovered to be deceased. Two decedents (1.37%) were discovered on their nursing pillows. One infant (0.69%) was found in a bouncy seat. One child (0.69%) was found in a sleeping bag on the floor and another (0.69%) on a blanket on the floor.

2. <u>Population Structure Analysis</u>

All major clusters contained both case and control individuals, indicating a lack of confounding batch effects, although ancestry proportions differed between cases and controls as expected, with cases having a much higher proportion of African-Americans (Fig. 2). Based on clustering in UMAP, self-reporting of race, and ancestry inference using GrafPop, individuals were divided into three broad ancestry groups: Asian (one case and 35 controls), African (68 cases and 15 controls), and European (76 cases and 526 controls).

3. <u>Gene Level Analysis</u>

3.1. Genes significantly enriched for functional variants in cases vs. controls

Using 9734 variants that passed the least stringent filtering criteria (P/LP on ClinVar, predicted pathogenic with at least three computational methods, and/or a frameshift, splice site, or stop gain variant), 18 genes were significant at FDR < 0.05 for having a higher case:control ratio for rate of variants than the baseline ratio of 0.645 (Fig. 3, Supplemental Table S1). For some of these genes, cases were more likely to have a variant than controls regardless of ancestry, whereas others only showed potentially pathogenic variants in cases of European or African ancestry (Fig. 4). Significant genes were largely driven by frameshift and splicing variants that were more common in cases than controls (Supplemental Table S2).

3.2. Gene ontology enrichment in cases vs. controls

Using the same 9734 variants from the gene-level analysis, 33 gene ontology terms had $P < 0.00001$ for the case:control ratio of rate of variants exceeding the baseline ratio of 0.645. Out of these 33 terms, 17 had lower P-values than any of their constituent genes (Supplemental Table S3). Notable terms among those 17 include Golgi lumen (GO:0005796) and maintenance of gastrointestinal epithelium (GO:0030277) driven by variants found across multiple mucin genes; positive regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043280) driven by *F2R* and *HSF1*; positive regulation of mitotic cell cycle (GO:0045931) driven by *TAL1* and *HSF1*; and several involving *RIPK2* including JUN kinase kinase kinase activity (GO:0004706), response to exogenous dsRNA (GO:0043330), positive regulation of T-helper

1 cell differentiation (GO:0045627), response to interleukin-1 (GO:0070555), response to interleukin-12 (GO:0070671), and cellular response to muramyl dipeptide (GO:0071225).

3.3. Gene ontology enrichment in cases only

Submission of the first set of 21 genes to STRING which were found with variants in cases only, and previously reported as P or LP in ClinVar revealed no significant enrichment in any GO terms (43). Submission of the second set of 626 genes that included the previous 21 genes in addition to genes containing variants predicted to be deleterious by at least 50% of the computational methods applied which revealed significant enrichment in 170 GO terms at FDR < 0.05 (including 24 GO terms with FDR ≤ 0.0001), with a protein-protein interaction P-value < 1.0e-16 indicating more connectivity in the network than would be expected from a random set of genes (Supplemental Table S4). Of the 24 most significantly enriched terms, notable enrichments included motor activity (GO:0003774), actin filament binding (GO:0051015), ATPase activity (GO:0016887), actin binding (GO:0003779) and actin filament-based process (GO:0030029) all by a factor of >2.5. An additional 5 GO terms were enriched by a factor of 10 including ryanodine-sensitive calcium-release channel activity (GO:0005219), calcium-induced calcium release activity (GO:0048763), ATP-dependent microtubule motor activity (GO:0008569), inner dynein arm (GO:0036156) and cardiac muscle fiber development (GO:0048739), though not as significantly (P≤0.05).

Submission of the third set of 988 genes to STRING which were found with variants in cases only, previously reported as P/LP in ClinVar, predicted by our computational methods to be deleterious and including any frameshift, stop-gained or splicing variants revealed significant enrichment in 91 GO terms at FDR < 0.05 (with 16 at FDR ≤0.0001), with protein-protein interaction significant at P < 1.1e-14 (Supplemental Table S5) (43). Of the 16 most significant GO terms, notable enrichment included actin filament binding (GO:0051015), by a factor of >3. An additional seven GO terms were enriched by a factor of 6 including microfilament motor activity (GO:0000146), actin-dependent ATPase activity (GO:0030898), spectrin binding (GO:0030507), calcium-release channel activity (GO:0015278), intracellular ligand-gated ion channel activity (GO:0005217), ligand-gated calcium channel activity (GO:0099604), and myosin complex (GO:0016459), though not as significantly (P<0.05).

4. <u>Variant Level Analysis</u>

4.1. Variants found in cases only

We performed a comparative analysis between variants in our cohort and variants in genes found in other relevant studies (12, 18, 20, 22) as well as Online Mendelian Inheritance in Man (OMIM) terms associated with SIDS and Death in Infancy.

We report here 156 variants of interest in 92 infants (63.4% of the cohort) in 86 genes, including 128 rare/ultra-rare variants in 71 genes that have been previously associated with SIDS/SUID/SUDP. The majority of these variants, 115, were missense variants. Twelve variants occurred in the splice region as well as five splice acceptor and two splice donor variants. Ten variants resulted in a premature stop and nine resulted in a frameshift, while two induced in-frame insertions and one, an in-frame deletion. The number of variants per case ranged from one to six, with a mean number of 2.5 variants per infant. Four variants were recurrent. Two variants in *CALM2* occurred in 3 infants, one was homozygous for one of these *CALM2* variants and two infants were heterozygous for each *CALM2* variant. One *CFTR* and one *ATM* variant each occurred in two infants as well. For individual genes, the number of variants ranged from 1 to 13. Fifty-six infants were found with only one of these variants of interest, however, multiple variants were identified in several decedents. Twenty-two infants were found with two variants. Four infants were found with three variants, and five infants were found with four variants. Three infants had five of these variants, and two were found with six variants. Forty-two of these genes can be characterized as cardiac genes, 23 as neurologic, while 13 are related to systemic function. An additional eight genes are related to various syndromes and are found in the Reactive Oxygen Species (ROS) pathway.

4.2. Reactive Oxygen Species (ROS) Pathway Related Genes (Table 2)

The previously reported pathogenic variants included 20 in eight genes found in the antioxidant pathway that plays a critical role in the hypoxic response, the ROS pathway, *AAGAB*, *ATM*, *BRCA1*, *CFTR*, *COL7A1*, *ITGB3*, *LAMB3*, and *SMAD3*. See Figure 5. ROS pathway variants were identified in 21 infants (13.8%). One infant had two of these variants and two of the same variants were found in two infants each, as previously stated. Exceptions to the inclusion of ultra-rare variants include two *CFTR* variants, and one *ITBG3* variant. These variants were found in infants of African descent (A) and are more common in that population, not meeting our criteria for rare/ultra-rare. However, these variants are reported here due to the overall rarity of the allele in the combined total population and the previously reported pathogenicity in ClinVar. See Table 2. See Supplemental Table S6 for details regarding the concurrence of the variants in each case and corresponding demographic data and relevant ME notes.

4.3. Genes previously implicated in SUID (Table 3)

In addition to the ROS pathway variants, we detected 128 variants of interest in genes that were previously implicated in SIDS/SUID/SUDP (12-24). Eighty-eight of these variants occurred in 43 genes related to cardiac conditions including generalized cardiomyopathy, specific cardiomyopathies such as arrhythmogenic right ventricular dysplasia and left ventricular noncompaction; cardiac arrhythmias including atrial and ventricular fibrillation; the channelopathies, Brugada syndrome, Long QT syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), in addition to several syndromes with a cardiac phenotype. Twenty-nine occurred in 22 genes related to neurologic function, including epilepsy, encephalopathy, ataxia, neuropathy and episodic pain syndrome, movement disorders such as dystonia and paralysis, intellectual disability and the polymalformation condition, Liang-Wang syndrome. Eleven additional variants were found in six genes related to systemic conditions and syndromes previously described in SIDS/SUID (18, 22). See Table 3.

4.3.1. Cardiac: Cardiomyopathy

Thirty-nine variants in 17 genes associated with cardiomyopathies and related conditions were found in 37 infants – five infants had two of these variants. These include *ABCC9, ACTN2, BAG3, DSG2, DSP, FLNC, JPH2, LAMA4, LDB3, MYBPC3, MYH6, MYPN, PRDM16, SCN5A, TNNC1, FPGT-TNNI3K*, *and TTN*. Five variants in three of these genes, *JPH2, LAMA4 and TNNC1*, were found in five infants and are associated with various cardiomyopathies in the absence of other conditions (OMIM:613873, OMIM:615235, OMIM:13243, OMIM:611879). One *LAMA4* variant, Arg1521His, has been previously reported in ClinVar as a variant of unknown significance (VUS) for cardiomyopathy and an unspecified cardiovascular phenotype (ClinVar:213607). The infant that was found with this variant had a family history of SIDS. Eighteen variants in five genes associated with cardiomyopathy and myopathy, *ACTN2*, *BAG3*, *FLNC, MYPN* and *TTN,* were found in 17 infants (OMIM:613881, OMIM:612954, OMIM:617047, OMIM:614065, OMIM:617336, OMIM:615248, OMIM:618655, OMIM:612158, OMIM:618654). Five variants in three genes, *LDB3*, *MYBPC3*, and *PRDM16,* associated with cardiomyopathy and left ventricular noncompaction were identified in four infants (OMIM:601493, OMIM:609452, OMIM:115197, OMIM:615396, OMIM:615373). One infant had two of these variants. Six variants in two genes, *DSG2* and *DSP* were identified in six different children that are associated with cardiomyopathy and right ventricular dysplasia (OMIM:610193, OMIM:612877, OMIM:607450, OMIM:605676). Two variants in two infants were found in *ABCC9* and *SCN5A* that are associated with both cardiomyopathy and atrial fibrillation (OMIM:608569, OMIM:614050, OMIM:601154, OMIM:614022). The variant in *SCN5A* is also associated with ventricular fibrillation (OMIM:603829), Brugada (OMIM:601144), Long QT syndrome (OMIM:603830), heart blocks (OMIM:113900, OMIM:113900), Sick Sinus syndrome (OMIM:608567), and susceptibility to SIDS (OMIM:272120). One variant in one gene associated with cardiomyopathy and a cardiac conduction disorder, *FPGT-TNNI3K*, was found in one infant (OMIM:616117). Two *MYH6* variants were found in two different infants that were related to cardiomyopathy (OMIM:613251, OMIM:613252), Sick Sinus syndrome (OMIM:614090), and cardiac defects including atrial septal defect (OMIM:614089). One infant in our cohort was found to have atrial septal defect at autopsy and another an unspecified heart defect at autopsy, but these variants did not occur in either of these infants. There were no autopsy reports available for the infants that carried these *MYH6* variants.

4.3.2. Cardiac: Congenital Conditions

Thirteen variants in five genes, *DCHS1*, *GJA1*, *NOTCH1*, *MYH11*, and *MYLK*, were found in 11 infants related to heart defects and congenital conditions in the absence of cardiomyopathy. Six variants were found in five infants in three genes associated with heart defects, *DCHS1*, *GJA1* and *NOTCH1*. These included mitral valve prolapse (OMIM:607829), atrioventricular septal defect (OMIM:600309), and aortic valve disease (OMIM:109730). One infant had a variant in both *GJA1* and *NOTCH1*. An autopsy report was available for only one of these five infants and no heart defect was found. Five *MYH11* variants associated with familial thoracic aortic aneurysm were found in four infants, one infant had two of these *MYH11* variants (OMIM:132900). Two *MYLK* variants, were found in two infants and are associated with familial thoracic aortic aneurysm (OMIM:613780). One missense (Pro190Leu) variant is reported to be a VUS for aortic aneurysm in ClinVar (ClinVar:520017). The child with the Pro190Leu variant had a family history of SUID, there were no relevant findings reported at autopsy other than the presence of focal intimal thickening in the right coronary artery.

4.3.3. Cardiac: Arrhythmias and Conduction Disorders

Five variants were found in five genes associated with cardiac arrhythmias and conduction disorders alone such as cardiac conduction effect, *AKAP10* (OMIM:115080), arrhythmogenic right ventricular dysplasia, *CTNNA3* (OMIM:615616), ventricular fibrillation*, DPP6* (OMIM:612956), arrhythmogenic right ventricular dysplasia, *TGFB3* (OMIM:107970), and *TMEM43* (OMIM:604400). These variants were found in five infants.

4.3.4. Channelopathies: Brugada syndrome, Long QT syndrome and CPVT

Thirty-two variants were found in 27 decedents in 17 genes related to the channelopathies Brugada and Long QT syndromes and CPTV. Nine variants in seven genes, *CACNB2, HCN4, KCND2, RANGRF, SCN10A, SLMAP, and TRPM4* were identified in eight decedents that have been implicated in Brugada syndrome in previous studies (20-24). Two of these variants in genes related to Brugada syndrome, *SCN10A* and *SLMAP,* were found in one infant. The *SCN10A* variant has been previously reported in ClinVar as a VUS for Brugada syndrome (ClinVar:641909) and also associated with the neurologic condition, episodic pain syndrome (OMIM:615551). The *SLMAP* variant has not been previously reported. Three variants in *SCN1B*, *SCN3B*, and *SCN5A* found in three infants, have been previously associated with Brugada syndrome as well as other arrhythmias (OMIM:612838, OMIM:613120, OMIM:601144). The *SCN3B* variant found has also been previously reported as P for death in infancy (ClinVar:213607). The *SCN5A* variant as previously discussed in section 4.3.1, has been associated with Long QT and SIDS among other conditions. The mother of the child in which the *SCN1B* variant was found was noted to have lost another child at three months of age to SIDS. Two infants were found with two additional variants in one gene, *CACNA1C*, that has been associated with Brugada syndrome (12, 16, 22, OMIM:611875) in addition to other arrhythmias (OMIM:601005, OMIM:609620), and Long QT syndrome (OMIM:618447). Six variants were found in three genes that have previously been linked to Long and/or Short QT Syndrome alone, *AKAP9*, *CALM2* and *KCNH2* (14-17, 20-23, OMIM:611820, OMIM:616249, OMIM:613688, OMIM:609620). A few children were found to have more than one of these variants. One infant had one variant in both *CACNA1C* and *AKAP9*, and one infant had two different *CALM2* variants, while a third infant was homozygous for one of these *CALM2* variants. Four variants in *ANK2* were found in four infants. Variants in this gene have been linked to Long QT syndrome in addition to other arrhythmias previously (16, 21, 22, OMIM:600919). The infant that was found with 2 different *CALM2* variants also had one of these *ANK2* variants. Six variants in *RYR2* were found in six infants. Variants in *RYR2* have been associated with CPVT (12, 13, 16, 20-22, OMIM:604772) and arrhythmogenic right ventricular dysplasia (OMIM:600996). One infant that had a variant in *RYR2* was also the infant found to be homozygous for one of the *CALM2* variants. Two variants in *TRDN* were identified in one infant. Variants in *TRDN* have been associated with CPVT through an AR mode of inheritance in OMIM (OMIM:615441).

4.4. Neurologic Disorders

Twenty-nine variants were found in 22 genes in 26 infants previously implicated in SIDS/SUID/SUDP that are related to neurologic disorders. Three infants had two of these variants each. Eleven variants in eleven infants were found in seven genes related to epilepsy, four in *CACNA1H*, one each in *CACNB4*, *EFHC1*, *GRIN1*, *GRIN2A*, *KCNQ3* and two in *SCN1A* previously implicated in SIDS/SUID/SUDP (20-24, OMIM:611942, OMIM:600669, OMIM:607682, OMIM:254770, OMIM:607631, OMIM:614254, OMIM:245570, OMIM:121201, OMIM:604403, and OMIM:607208). One *SCN1A* missense variant, Asp987Glu, has been previously reported in ClinVar to be LP for severe myoclonic epilepsy in infancy (SMEI), also known as Dravet syndrome (ClinVar:520017), a condition which has been previously implicated in SIDS/SUID/SUDP and

SUDEP (13, 16, 18, 22-24). Five variants were found in four genes in five children related to epilepsy and other conditions *KCNMA1*, *KCNT1*, *SCN2A* and *SLC2A1* (OMIM:618596, OMIM:617643, OMIM:609446, OMIM:615005, OMIM:614959, OMIM:613721, OMIM:607745, OMIM:618924, OMIM:614847, OMIM:608885) Two infants were found with two different *KCNMA1* variants associated with the polymalformation condition, Lian-Wang syndrome (OMIM:618729). The infant with the *KCNQ3* variant also had a variant in *SLC2A1* associated with dystonia (OMIM:601042), childhood onset of GLUT1 deficiency syndrome 2 of AD inheritance (OMIM:612126), Stomatin-deficient cryohydrocytosis with neurologic defects, AD, (OMIM:608885) as well as epilepsy (OMIM:614847). This infant was noted to have a "well developed infant brain with isolated microglial nodules" by the ME. Five variants in five genes were found in five infants related to encephalopathy, *CHD2, DNM1L, GRIN2B*, *KCNA2*, and *RANBP2* (OMIM:602119, OMIM:614388, OMIM:616139, OMIM:616366, OMIM:608033). One *SCN8A* variant found in one infant was associated with both epilepsy and encephalopathy (OMIM:614558, OMIM:618364). The infant with the *RANBP2* variant also had the *KCNT1* variant, related to epilepsy (OMIM:615005), as previously stated, and encephalopathy (OMIM:614959). The infant with the *DNM1L* variant was noted at autopsy to have "neuronal changes consistent with hyperacute hypoxia ischemia". Two additional infants were found to have one variant each in *SCN11A*, related to episodic pain syndrome and neuropathy (OMIM:615552, OMIM:615548). Another two children were found with a variant each in *SCN9A* also related to neuropathy (OMIM:243000, OMIM:133020. Two variants were identified in two children related to intellectual disability, *CLCN4* and *DYRK1A* (OMIM:300114, OMIM:614104) The infant with the *DYRK1A* variant also had the *KCNMA1* variant. Finally, one *SCN4A* variant was identified in one infant related to movement disorders and paralysis (OMIM:168300, OMIM:608390, OMIM:170500, OMIM:613345). This variant is reported as VUS in ClinVar for Hyperkalemic periodic paralysis (ClinVar:1899177).

4.5. Systemic/Syndromic Conditions (Tables 3 and 4)

Eleven variants were found in six genes in eight infants that are reported to be VUS, LP, or P for various syndromes for which there was no noted diagnosis at the time of death. Variants in six of these genes have been previously implicated in SIDS/SUID/SUDP*,* including *CHRNA1, FLNA, PHOX2B, POLG, TBX5, and TSC1 (22).* The variant in *CHRNA1* has been linked to Lethal multiple pterygium syndrome, (ClinVar:466178). The variant in *FLNA* has been associated with multiple conditions in OMIM including, Otopalatodigital syndrome (OMIM:311300), Melnick-Needles syndrome (OMIM:309350), Cardiac valvular dysplasia (OMIM:314400), FG syndrome (OMIM:300321), Periventricular heterotopia (OMIM:300049), Terminal osseous dysplasia (OMIM:300244). The variant in *PHOX2B* has been implicated in Central hypoventilation syndrome (VUS, ClinVar:486030, OMIM:209880). The *POLG* variant has been associated with Progressive sclerosing poliodystrophy (LP, ClinVar:619308) and Progressive external ophthalmoplegia with DNA deletions (OMIM:157640). The *TBX5* variant has been previously associated with Holt-Oram syndrome (OMIM:142900). Both of the *TSC1* variants have been associated with Tuberous Sclerosis (LB/VUS, ClinVar:237715, LB/VUS, ClinVar:237714, OMIM:191100), Focal cortical dysplasia (OMIM:607341) and Lymphangioleiomyomatosis (OMIM:606690). The infant in which the *PHOX2B* variant was identified was noted to be "in the 10th percentile of growth for age", and to have "mesenteric lymphadenopathy, hepatosplenomegaly, adrenal hypoplasia" at autopsy. This infant was also found to have one of the *TBX5* variants. The child in which the *CHRNA1* variant was found was also found to have a *DYNC1H1* variant (discussed in the next paragraph) previously reported as P in ClinVar for spinal muscular atrophy, a condition of AD inheritance (ClinVar:30034). This child was noted to have been hospitalized for 10 days following birth for unspecified reasons. See Tables 3 and S6.

Eight rare (<0.01%) variants were incidentally found in seven genes that are reported to be associated in ClinVar and OMIM with various syndromes, *ALB* (P, Congenital analbuminemia, ClinVar:156320, OMIM:616000), (Dysalbuminemic hyperthyroxinemia, OMIM:615999); *C12orf65/MTHFR* (P, Spastic paraplegia, ClinVar:214192, OMIM:613559); *DYNC1H1* (P, Spinal muscular atrophy, ClinVar:30034, OMIM:158600), *GPR98/ADGRV1* (P, Usher Syndrome, Febrile Seizures, ClinVar:6798, OMIM:604352, OMIM:605472); *HBA2* (P, Not provided, ClinVar:439116, Thalassemia alpha, OMIM:604131, Hemoglobin H disease, OMIM:613978, Heinz body anemia, OMIM: 140700); *PIEZO2* (P, Inborn genetic diseases, ClinVar:521668, Arthrogryposis distal, OMIM:114300, OMIM:108145, OMIM:617146, Marden-Walker syndrome, OMIM:248700); and *SPG7* (Spastic Parapalegia, P, ClinVar:6816, OMIM:607259); Variants in these genes have not been previously associated with SIDS/SUID. Two GPR98/ADGRV1 variants in one infant were identified that are related to familial febrile seizures and Usher syndrome, both of digenic and AR inheritance. The first results in a premature stop and has been previously reported to be P for these conditions (ClinVar:6798). The second variant is a missense variant that is reported to be a VUS for these conditions (ClinVar:198666). This variant is found more commonly in the Northern European (NE) population (AF=0.065%, NE; Total AF=0.035%) and does not meet our criteria for rare. (The infant in which this variant was found was of NE ethnicity.) Due to the mode of inheritance of these conditions, this variant is also likely significant for the development of disease, so both are included here. See Tables 4 and S6.

4.6. Group Analysis: Average Age at Death

The age of death was adjusted according to gestational age for those infants that were noted to have been born prematurely. Infants were grouped according to the type and number of variants each were found to have, cardiac, neurologic, ROS pathway, and systemic/syndromic. The average age of death was calculated for each group among children that were found to have only one variant. A single variant in a cardiac related gene was found in 31 infants for whom the age of death was known. Thirteen infants were found with a single variant related to neurologic function whose age of death was known and 12 infants were identified with a single ROS pathway gene variant. There were only two infants with one variant among the systemic/syndromic group, so this group was excluded from the analysis. On average, the 31 infants with the single cardiac gene variant died at 9.9 ± 5.6 weeks of age, whereas the 13 infants that were found to have a single variant in a gene related to neurologic function died on average at 15.0 ± 7.3 weeks. The 12 infants with a single variant in a ROS pathway gene died at the average age of 15.4 ± 13.0 weeks of age. ANOVA was run in R and revealed that these differences were significant (P=0.045). See Figure 6. See Table S7 for a full list of abbreviations used in this manuscript.

Discussion

We set out to explore the potential contribution of gene variants to the etiology of SUID. We identified numerous variants in genes associated with SUID. Some of these are variants known for their involvement in cardiac diseases, neurological disorders, the regulation of neuronal excitability and the response to hypoxia and oxidative stress (ROS). Gene enrichment studies in cases further confirmed the validity of these findings.

ROS Pathway Variants

Each of the genes in the ROS pathway in which P/LP variants were identified contributes to the regulation of the response to hypoxia, in particular the activation of HIF1α and the production of ROS (45). For example, *AAGAB,* highly expressed in the brain, regulates *PTEN* nuclear translocation to promote the functional neuronal recovery following hypoxic-ischemic induced brain injury (46). *ATM* is activated by hypoxia and re-oxygenation and thus acts as a redox sensor (47). It plays a critical role in maintaining cellular redox homeostasis (47). Dysfunction in *ATM* has been implicated in heart failure and sudden death. *BRCA1* plays a major role in the hypoxic response by regulating HIF-1α stability, and also rescues neurons from cerebral ischemia/perfusion injury through the NRF2 signaling pathway (48). *CFTR* is well studied in cystic fibrosis – and associated with respiratory failure, but *CFTR* also functions as a regulator of ROS and has been associated with impairment in oxidative phosphorylation (49). *CFTR* belongs to the ATP binding cassette (ABC) transporter superfamily and is also widely expressed in the CNS (50). *COL7A1* is also a regulator in the hypoxic response and HIF-1α, and it is

activated by NF-kB (51). *ITGB3* is required for sustained TGF-β pathway activation (52). It is activated by HIF1α in hypoxia and its knockdown has been associated with increased apoptosis and reduced neuronal survival and migration, particularly under hypoxic conditions (52). *ITGB3* is also associated with acute coronary syndromes (53). HIF1α activates the *TGFβ-SMAD3* pathway, and both play a critical role in the hypoxic response and response to injury (54). *SMAD3* is also regulated by serotonin (55) which has been implicated in SUID (56). Variants in this gene have been described in patients that died of sudden cardiac death, heart failure and aortic aneurysm (57-61).

Potential genetic contributors to SUID vulnerability

Our findings provide further evidence that genetic markers are important indicators for SUID and may contribute to their vulnerability as hypothesized in the triple risk hypothesis (25). The number of genetic variations associated with cardiac and neurological disturbances was striking and could contribute to an increased vulnerability during the autoresuscitation response, which critically depends on functional cardiorespiratory coupling and the generation of a hypoxic response. An important consideration that emerges from this and prior genetic studies are the implications for later stages of life. Most individuals with these variants will likely survive the critical period that characterizes SUID but may be at risk for sudden death later in life when faced with other stressors or conditions. For example, we found variants in *SCN1A* and *SCN8A*, genes which are known to be associated with SUDEP and have been previously described in SUID, though recognizable seizures had not been observed in these individuals (12, 13, 16, 22-24, 62, 63). We also found many variants in genes associated with cardiac disorders linked to sudden death. For example, Long QT syndrome (*CACNA1C*, *KCNH2*) which has been previously implicated in SUID, though these disorders had not yet been observed in these infants (12, 14, 16, 20-23, 64, 65). In addition, we identified cases with variants previously reported in ClinVar to be LP/P for conditions such as blood disorders (*ALB, HBA2*) that have been associated with fatal outcomes, but which were not diagnosed in the infants in which these variants were found (66, 67). This is interesting, since transition from fetal hemoglobin to that of adults has been implicated in SIDS (68). Adult hemoglobin, which has a lower oxygen affinity, replaces fetal hemoglobin postnatally over a period of 6 months (69). Variants associated with deafness (*GPR98/ADGRV1*), are also interesting, since inner ear defects have previously been implicated in some SUID cases (70, 71). Several of the variants found in our study were previously reported to be pathogenic for disorders of the muscles including spasticity or parapalegia, (*C12orf65/MTRFR*, *DYNC1H1, PIEZO2, SPG7*). Gene enrichment studies aligned with these findings in that notable enrichments in cases included motor activity (GO:0003774). Some of these disorders have been associated with respiration dysfunction which could contribute to an individual's vulnerability.

We found many genes associated with the regulation of the hypoxic response and ROS production as mentioned above. HIF-1α and ROS are produced under conditions of chronic intermittent hypoxia (72), conditions that are seen in apnea of prematurity (73) and in recurrent apneas thought to precede SUID. ROS production is a major driver of dysautonomia and could contribute to an abnormal hypoxic response and failed arousal. Disturbances in the regulation of HIF1α and ROS production could exaggerate the accumulation of ROS in response to conditions like intermittent hypoxia thereby increasing the vulnerability of the child to succumb to an exogenous stressor experienced e.g. under prone conditions. This is consistent with pathological discoveries made in children that succumbed to SIDS (74-76). As previously discussed, the identification of a variant is not sufficient to predict how a variant affects the hypoxic response at the neuronal level, let alone at the level of the child (77). Follow-up studies that generate these human variants in animal models or in IPSCs or human organoids could provide important additional mechanistic clues. Without these functional insights, these discoveries provide novel evidence that aside of the known cardiac, neurological, and metabolic genes, it will be important to consider also genes associated with the regulation of the hypoxic response as potential biomarkers for SUID. However, at this point it is too early to consider certain variants or groups of variants as biomarkers for SUID.

Statistical analysis of genes and pathways provided novel biological insight. For example, the *F2R* gene contained a splice site variant that was detected in six cases, including both individuals of European and African descent, but only one control. While primarily a coagulation factor, *F2R* has also been found to block neuronal apoptosis (78), which has been implicated in SIDS, particularly in the medulla (79). Variants in both *F2R* and *HSF1* that were more frequent in cases than controls were responsible for the significance of GO:0043280 (positive regulation of cysteine-type endopeptidase activity involved in apoptotic process) in our analysis. Another finding of note was that SIDS cases were more likely than controls

to have functional variants in mucin genes. Disruptions to mucin genes could lead to pathogen susceptibility and/or respiratory difficulties (80). These variants found through statistical analysis, however, were not included here because they did not pass our rigorous filtering, which excluded all variants found in controls. The absolute exclusion of these variants might not necessarily make sense when investigating such a complex disorder as SUID. The triple risk hypothesis suggests that there will be many infants with similar genetic vulnerabilities, not exposed to an exogenous stressor, that will survive infancy, so perhaps excluding variants found in controls or that are found more commonly in a population is not the best approach when examining these cases. Another example of this is that in our cohort, 36 children (24.8%) were found with variants in genes involved in serotonin binding and reception which have been implicated previously in SUID (81). However, none of these variants made it past our filtering mostly because they were found more frequently in the overall population and thus excluded, but it is possible that some of these variants could have contributed to the overall vulnerability of the infant. This filtering approach is a possible limitation of this study.

Study Limitations

The lack of complete medical records and detailed notes that were available for each decedent was a limitation of this study. We were able to establish demographic aspects of the cohort such as ethnicity, biological sex, and age at death for all but a small proportion of the cohort. However, we were not able to completely characterize the cohort regarding factors such as the presence of recent illness, medical history, environmental exposures, or even the sleeping circumstances at the time of death. Autopsy records were accessible for fifty of the infants, with limited notes available for the remainder of the cohort. Some cases had only very limited demographic data as mentioned previously without any additional comments. Even within the autopsy reports, the amount of detail varied. This information helps to identify important phenotypic characteristics of an individual and gives investigators insight into their genetic profile. Detailed phenotypic characteristics are highly valuable for establishing a potential causation regarding the genotype of an individual. In addition, parental data was not available for this analysis, and variants were assumed to be *de novo*. Analysis of trios where this could be confirmed would further strengthen the study.

Mismatched racial proportions between our controls and cases are another possible limitation. For the gene level analysis, we demonstrated that significant genes were not confounded by racial differences in the number of variants present (Figure 4). At the variant level, this discrepancy was addressed by matching the appropriate allele frequency in gnomAD specific to the ethnicity of the infant in which candidate alleles were identified.

Conclusion

The present study is one of the first whole genome sequencing studies of infants that died unexpectedly and suddenly. Consistent with the triple risk hypothesis, we find numerous gene variants that could contribute to an increased vulnerability to sudden death. Interestingly, many of those genes have previously been implicated in other causes of sudden death including cardiac death or sudden death in epilepsy. Thus, we hypothesize that many children will survive the critical time period associated with SUID. They will carry this vulnerability into adult life, when they might face other stressors for example those known to be associated with sudden cardiac death. This highlights the importance of recognizing vulnerability early in life, which may not only help to prevent SUID, but sudden death in general.

Data Availability

Data from which the determinations of this study are made have been included in the supplementary data. We will make the de-identified data available to physician scientists that would like to use these data for research.

Acknowledgments

We would like to thank John and Heather Kahan for their great efforts, financial support, and inspiration to conduct this study.

Funding Statement

This study was funded by the Aaron Matthew SIDS Research Guild, Seattle Children's Research Institute, and NIH Grants R01 HL126523(awarded to J.-M.R.), P01 HL090554 (awarded to J.-M.R.)

Author Contributions

Conceptualization: JMR, AMB, LVC, KAA, EC; Data curation: EC, AT, AMB, LVC, AS, DM, SB, ZM, AN; Formal analysis: EC, AT, LVC, AMB, KA, JMR; Funding acquisition: JMR; Investigation AMB, LVC, EC, AT, KA, LQ, JMLF, EAH, DJ, JMR; Methodology AMB, LVC, KAA, EC, LAQ, EAH, DJ; Project administration: AMB, CMP, TMB; Resources JMR, JMLF; Software: EC, JMLF, AT, LVC; Supervision JMR, EC, KAA, LVC, AMB; Validation AMB, LVC, EC, KAA, AT, LAQ, JMLF, DJ, EAH, TMB, CMP, AS, DM, SB, ZM, AN, JMR; Visualization JMR, AMB, LVC; Writing-original draft JMR, AMB, LVC; Writing-review & editing JMR, AMB, LVC, KAA, EC, AS;

Ethics Declaration

Samples obtained from the NIH NBB (https://neurobiobank.nih.gov/) were exempt from the requirement of informed consent because the individuals providing the samples were deceased. However, donor recruitment sites for the NIH NBB typically obtain authorization from the parent/s of the individual. Archived samples obtained from the University of Washington and Seattle Children's Hospital were granted a waiver for informed consent through Seattle Children's Research Institute's Institutional Review Board (IRB), which approved the study. Informed consent was obtained for samples which did not meet criteria for the waiver granted by the IRB. This study is HIPAA, GDPR and NIH compliant.

Conflict of Interest

The authors declare that they have no interests, financial or otherwise, related to this study that would influence their objectivity or the content of this manuscript.

Affiliations

[1]Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA; [2]Department of Neurological Surgery, [3]Department of Pediatrics, and [4]Department of Neurology, University of Washington School of Medicine, Seattle WA, [5]Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA; [6]Bioinformatics and Research Scientific Computing, Seattle Children's Research Institute, Seattle WA; [7]AI for Good Research Lab, Microsoft, Redmond WA; [8]Microsoft Genomics Team, Redmond WA; [9]Department of Research, Rady Children's Hospital-San Diego, San Diego, CA. [10]Let's Get Checked, Monrovia, CA

References

1. American SIDS Institute. *Definitions*. "SIDS". https://www.sids.org/what-is-sidssuid/definitions/. Accessed Nov. 8, 2022.
2. Lavista Ferres J. et al. "Distinct Populations of Sudden Unexpected Infant Death Based on Age". *Pediatrics*. Jan 2020. PMID: 31818863.
3. Center for Disease Control and Prevention. Sudden Unexpected Infant Death and Sudden Infant Death Syndrome. "Data and Statistics". Accessed Dec. 4, 2021. https://www.cdc.gov/sids/data.htm
4. Allen K. et al. "Factors Associated with Age of Death in Sudden Unexpected Infant Death". *Acta Paediatrica*. Jan. 2021. PMID: 32304589.
5. Anderson T. et. al. "Maternal Smoking Before and During Pregnancy and the Risk of Sudden Unexpected Infant Death". *Pediatrics*. Jan 2019. PMCID: PMC6564075 . Accessed Nov. 5, 2021. 5.

6. Mitchell EA, Krous HF. Sudden unexpected death in infancy: a historical perspective. J Paediatr Child Health. 2015 Jan;51(1):108-12. doi: 10.1111/jpc.12818. PMID: 25586853.
7. Mitchell EA. Cot death: should the prone sleeping position be discouraged? J Paediatr Child Health. 1991 Dec;27(6):319-21. doi: 10.1111/j.1440-1754.1991.tb00409.x. PMID: 1756070.
8. Goldwater PN. Infection: the neglected paradigm in SIDS research. Arch Dis Child. 2017 Aug;102(8):767-772. doi: 10.1136/archdischild-2016-312327. Epub 2017 Jan 23. PMID: 28115322; PMCID: PMC5537520.
9. Mitchell E. et al. "Geographic Variation in Sudden Unexpected Infant Death in the United States". *Pediatrics*. May 2020. PMID: (missing). Accessed Nov. 5, 2021.
10. Dales, Robert et al. "Air pollution and sudden infant death syndrome." *Pediatrics* vol. 113,6 (2004): e628-31. doi:10.1542/peds.113.6.e628
11. Mitchell EA. The changing epidemiology of SIDS following the national risk reduction campaigns. Pediatr Pulmonol Suppl. 1997;16:117-9. doi: 10.1002/ppul.1950230865. PMID: 9443233.
12. Halvorsen M, Gould L, Wang X, Grant G, Moya R, Rabin R, Ackerman MJ, Tester DJ, Lin PT, Pappas JG, Maurano MT, Goldstein DB, Tsien RW, Devinsky O. De novo mutations in childhood cases of sudden unexplained death that disrupt intracellular Ca2+ regulation. Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):e2115140118. doi: 10.1073/pnas.2115140118. PMID: 34930847; PMCID: PMC8719874.
13. Chahal CAA, Tester DJ, Fayyaz AU, Jaliparthy K, Khan NA, Lu D, Khan M, Sahoo A, Rajendran A, Knight JA, Simpson MA, Behr ER, So EL, St Louis EK, Reichard RR, Edwards WD, Ackerman MJ, Somers VK. Confirmation of Cause of Death Via Comprehensive Autopsy and Whole Exome Molecular Sequencing in People With Epilepsy and Sudden Unexpected Death. J Am Heart Assoc. 2021 Dec 7;10(23):e021170. doi: 10.1161/JAHA.121.021170. Epub 2021 Nov 24. PMID: 34816733; PMCID: PMC9075361.
14. Moore JP, Gallotti RG, Shannon KM, Bos JM, Sadeghi E, Strasburger JF, Wakai RT, Horigome H, Clur SA, Hill AC, Shah MJ, Behere S, Sarquella-Brugada G, Czosek R, Etheridge SP, Fischbach P, Kannankeril PJ, Motonaga K, Landstrom AP, Williams M, Patel A, Dagradi F, Tan RB, Stephenson E, Krishna MR, Miyake CY, Lee ME, Sanatani S, Balaji S, Young ML, Siddiqui S, Schwartz PJ, Shivkumar K, Ackerman MJ. Genotype Predicts Outcomes in Fetuses and Neonates With Severe Congenital Long QT Syndrome. JACC Clin Electrophysiol. 2020 Nov;6(12):1561-1570. doi: 10.1016/j.jacep.2020.06.001. Epub 2020 Aug 26. PMID: 33213816; PMCID: PMC7679474.
15. Clemens DJ, Gray B, Bagnall RD, Tester DJ, Giudicessi JR, Maleszewski JJ, Crotti L, Schwartz PJ, Matthews E, Semsarian C, Behr ER, Ackerman MJ. Prevalence and Phenotypic Correlations of Calmodulinopathy-Causative CALM1-3 Variants Detected in a Multicenter Molecular Autopsy Cohort of Sudden Unexplained Death Victims. Circ Genom Precis Med. 2020 Dec;13(6):e003032. doi: 10.1161/CIRCGEN.120.003032. Epub 2020 Nov 15. PMID: 33191766.
16. Chahal CAA, Salloum MN, Alahdab F, Gottwald JA, Tester DJ, Anwer LA, So EL, Murad MH, St Louis EK, Ackerman MJ, Somers VK. Systematic Review of the Genetics of Sudden Unexpected Death in Epilepsy: Potential Overlap With Sudden Cardiac Death and Arrhythmia-Related Genes. J Am Heart Assoc. 2020 Jan 7;9(1):e012264. doi: 10.1161/JAHA.119.012264. Epub 2019 Dec 21. PMID: 31865891; PMCID: PMC6988156.
17. Tester DJ, Wong LCH, Chanana P, Gray B, Jaye A, Evans JM, Evans M, Fleming P, Jeffrey I, Cohen M, Tfelt-Hansen J, Simpson MA, Behr ER, Ackerman MJ. Exome-Wide Rare Variant Analyses in Sudden Infant Death Syndrome. J Pediatr. 2018 Dec;203:423-428.e11. doi: 10.1016/j.jpeds.2018.08.011. Epub 2018 Sep 26. PMID: 30268395; PMCID: PMC6394853.
18. Gray B, Tester DJ, Wong LC, Chanana P, Jaye A, Evans JM, Baruteau AE, Evans M, Fleming P, Jeffrey I, Cohen M, Tfelt-Hansen J, Simpson MA, Ackerman MJ, Behr ER. Noncardiac genetic predisposition in sudden infant death syndrome. Genet Med. 2019 Mar;21(3):641-649. doi: 10.1038/s41436-018-0131-4. Epub 2018 Aug 24. PMID: 30139991.
19. Männikkö R, Wong L, Tester DJ, Thor MG, Sud R, Kullmann DM, Sweeney MG, Leu C, Sisodiya SM, FitzPatrick DR, Evans MJ, Jeffrey IJM, Tfelt-Hansen J, Cohen MC, Fleming PJ, Jaye A, Simpson MA, Ackerman MJ, Hanna MG, Behr ER, Matthews E. Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study. Lancet. 2018 Apr 14;391(10129):1483-1492. doi: 10.1016/S0140-6736(18)30021-7. Epub 2018 Apr 5. PMID: 29605429; PMCID: PMC5899997.
20. Tester DJ, Wong LCH, Chanana P, Jaye A, Evans JM, FitzPatrick DR, Evans MJ, Fleming P, Jeffrey I, Cohen MC, Tfelt-Hansen J, Simpson MA, Behr ER, Ackerman MJ. Cardiac Genetic Predisposition in Sudden Infant Death Syndrome. J Am Coll Cardiol. 2018 Mar 20;71(11):1217-1227. doi: 10.1016/j.jacc.2018.01.030. PMID: 29544605.

21. Baruteau AE, Tester DJ, Kapplinger JD, Ackerman MJ, Behr ER. Sudden infant death syndrome and inherited cardiac conditions. Nat Rev Cardiol. 2017 Dec;14(12):715-726. doi: 10.1038/nrcardio.2017.129. Epub 2017 Sep 7. PMID: 28880023.
22. Koh HY, Haghighi A, Keywan C, Alexandrescu S, Plews-Ogan E, Haas EA, Brownstein CA, Vargas SO, Haynes RL, Berry GT, Holm IA, Poduri AH, Goldstein RD. Genetic Determinants of Sudden Unexpected Death in Pediatrics. Genet Med. 2022 Apr;24(4):839-850. doi: 10.1016/j.gim.2021.12.004. Epub 2022 Jan 10. PMID: 35027292; PMCID: PMC9164313.
23. Keywan C, Poduri AH, Goldstein RD, Holm IA. Genetic Factors Underlying Sudden Infant Death Syndrome. Appl Clin Genet. 2021 Feb 15;14:61-76. doi: 10.2147/TACG.S239478. PMID: 33623412; PMCID: PMC7894824.
24. Rochtus AM, Goldstein RD, Holm IA, Brownstein CA, Pérez-Palma E, Haynes R, Lal D, Poduri AH. The role of sodium channels in sudden unexpected death in pediatrics. Mol Genet Genomic Med. 2020 Aug;8(8):e1309. doi: 10.1002/mgg3.1309. Epub 2020 May 25. PMID: 32449611; PMCID: PMC7434613.
25. Guntheroth WG, Spiers PS. The triple risk hypotheses in sudden infant death syndrome. Pediatrics. 2002 Nov;110(5):e64. doi: 10.1542/peds.110.5.e64. PMID: 12415070.
26. Rognum TO, Saugstad OD. Biochemical and immunological studies in SIDS victims. Clues to understanding the death mechanism. Acta Paediatr Suppl. 1993 Jun;82 Suppl 389:82-5. doi: 10.1111/j.1651-2227.1993.tb12886.x. PMID: 8374202.
27. Vivekanandarajah A, Nelson ME, Kinney HC, Elliott AJ, Folkerth RD, Tran H, Cotton J, Jacobs P, Minter M, McMillan K, Duncan JR, Broadbelt KG, Schissler K, Odendaal HJ, Angal J, Brink L, Burger EH, Coldrey JA, Dempers J, Boyd TK, Fifer WP, Geldenhuys E, Groenewald C, Holm IA, Myers MM, Randall B, Schubert P, Sens MA, Wright CA, Roberts DJ, Nelsen L, Wadee S, Zaharie D, Haynes RL; PASS Network. Nicotinic Receptors in the Brainstem Ascending Arousal System in SIDS With Analysis of Pre-natal Exposures to Maternal Smoking and Alcohol in High-Risk Populations of the Safe Passage Study. Front Neurol. 2021 Mar 10;12:636668. doi: 10.3389/fneur.2021.636668. PMID: 33776893; PMCID: PMC7988476.
28. Kinney HC, Haynes RL. The Serotonin Brainstem Hypothesis for the Sudden Infant Death Syndrome. J Neuropathol Exp Neurol. 2019 Sep 1;78(9):765-779. doi: 10.1093/jnen/nlz062. PMID: 31397480; PMCID: PMC6934437.
29. Nasirova N, Quina LA, Agosto-Marlin IM, Ramirez JM, Lambe EK, Turner EE. Dual recombinase fate mapping reveals a transient cholinergic phenotype in multiple populations of developing glutamatergic neurons. J Comp Neurol. 2020 Feb 1;528(2):283-307. doi: 10.1002/cne.24753. Epub 2019 Aug 22. PMID: 31396962; PMCID: PMC6889053.
30. Garcia AJ 3rd, Koschnitzky JE, Ramirez JM. The physiological determinants of sudden infant death syndrome. Respir Physiol Neurobiol. 2013 Nov 1;189(2):288-300. doi: 10.1016/j.resp.2013.05.032. Epub 2013 Jun 2. PMID: 23735486; PMCID: PMC3812300.
31. Let's Get Checked. 2023. Unpublished internal company document. Monrovia, CA.
32. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009 Aug 15;25(16):2078-9. doi: 10.1093/bioinformatics/btp352. Epub 2009 Jun 8. PMID: 19505943; PMCID: PMC2723002.
33. Stacklies W, Redestig H, Scholz M, Walther D, Selbig J. pcaMethods--a bioconductor package providing PCA methods for incomplete data. Bioinformatics. 2007 May 1;23(9):1164-7. doi: 10.1093/bioinformatics/btm069. Epub 2007 Mar 7. PMID: 17344241.
34. McInnes et al., (2018). UMAP: Uniform Manifold Approximation and Projection. Journal of Open Source Software, 3(29), 861, https://doi.org/10.21105/joss.00861
35. Yumi Jin and others, GRAF-pop: A Fast Distance-Based Method To Infer Subject Ancestry from Multiple Genotype Datasets Without Principal Components Analysis, *G3 Genes|Genomes|Genetics*, Volume 9, Issue 8, 1 August 2019, Pages 2447–2461, https://doi.org/10.1534/g3.118.200925
36. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012 Apr-Jun;6(2):80-92. doi: 10.4161/fly.19695. PMID: 22728672; PMCID: PMC3679285.
37. Pedersen BS, Brown JM, Dashnow H, Wallace AD, Velinder M, Tristani-Firouzi M, Schiffman JD, Tvrdik T, Mao R, Best DH, Bayrak-Toydemir P, Quinlan AR. Effective variant filtering and expected candidate variant yield in studies of rare

human disease. NPJ Genom Med. 2021 Jul 15;6(1):60. doi: 10.1038/s41525-021-00227-3. PMID: 34267211; PMCID: PMC8282602.
38. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010 Sep;38(16):e164. doi: 10.1093/nar/gkq603. Epub 2010 Jul 3. PMID: 20601685; PMCID: PMC2938201.
39. Cingolani P, Patel VM, Coon M, Nguyen T, Land SJ, Ruden DM, Lu X. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift. Front Genet. 2012 Mar 15;3:35. doi: 10.3389/fgene.2012.00035. PMID: 22435069; PMCID: PMC3304048.
40. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME; Genome Aggregation Database Consortium; Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May 27. Erratum in: Nature. 2021 Feb;590(7846):E53. Erratum in: Nature. 2021 Sep;597(7874):E3-E4. PMID: 32461654; PMCID: PMC7334197.
41. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5. doi: 10.1093/nar/gkt1113. Epub 2013 Nov 14. PMID: 24234437; PMCID: PMC3965032.
42. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001 Nov 1;125(1-2):279-84. doi: 10.1016/s0166-4328(01)00297-2. PMID: 11682119.
43. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. doi: 10.1093/nar/gky1131. PMID: 30476243; PMCID: PMC6323986.
44. Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), {Dec. 2022}. World Wide Web URL: https://omim.org/
45. Yuan, G., Peng, Y. J., Reddy, V. D., 106. Makarenko, V. V., Nanduri, J., Khan, S. A., Garcia, J. A., Kumar, G. K., Semenza, G. L., & Prabhakar, N. R. (2013). Mutual antagonism between hypoxia-inducible factors 1α and 2α regulates oxygen sensing and cardio-respiratory homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, *110*(19), E1788–E1796. https://doi.org/10.1073/pnas.1305961110
46. Dai, Chunfang et al. “Aagab acts as a novel regulator of NEDD4-1-mediated Pten nuclear translocation to promote neurological recovery following hypoxic-ischemic brain damage.” *Cell death and differentiation* vol. 28,8 (2021): 2367-2384. doi:10.1038/s41418-021-00757-4
47. Hammond, Ester M, and Amato J Giaccia. “The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation.” *DNA repair* vol. 3,8-9 (2004): 1117-22. doi:10.1016/j.dnarep.2004.03.035
48. Xu, Pengfei et al. “Breast cancer susceptibility protein 1 (BRCA1) rescues neurons from cerebral ischemia/reperfusion injury through NRF2-mediated antioxidant pathway.” *Redox biology* vol. 18 (2018): 158-172. doi:10.1016/j.redox.2018.06.012
49. Ntimbane, Thierry et al. “Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.” *The Clinical biochemist. Reviews* vol. 30,4 (2009): 153-77.
50. Vasiliou, Vasilis et al. “Human ATP-binding cassette (ABC) transporter family.” *Human genomics* vol. 3,3 (2009): 281-90. doi:10.1186/1479-7364-3-3-281
51. Amelio I, Mancini M, Petrova V, Cairns RA, Vikhreva P, Nicolai S, Marini A, Antonov AA, Le Quesne J, Baena Acevedo JD, Dudek K, Sozzi G, Pastorino U, Knight RA, Mak TW, Melino G. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10869-E10878. doi: 10.1073/pnas.1808314115. Epub 2018 Oct 31. PMID: 30381462; PMCID: PMC6243248.

52. Sesé, Marta et al. “Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signaling and malignant features *in vitro* and *in vivo*.” *Oncotarget* vol. 8,70 114856-114876. 12 Dec. 2017, doi:10.18632/oncotarget.23145
53. Damar, İbrahim Halil, and Recep Eroz. “The Association of Hereditary Prothrombotic Risk Factors with ST-ElevationMyocardial Infarction.” *Medeniyet medical journal* vol. 35,4 (2020): 295-303. doi:10.5222/MMJ.2020.67366
54. Basu, Rajit K et al. “Interdependence of HIF-1α and TGF-β/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression.” *American journal of physiology. Renal physiology* vol. 300,4 (2011): F898-905. doi:10.1152/ajprenal.00335.2010
55. Chen, Chunyan et al. “Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1/Smad3-mediated fibrotic responses through 5-HT(2A) receptors.” *Molecular and cellular biochemistry* vol. 397,1-2 (2014): 267-76. doi:10.1007/s11010-014-2194-0
56. Cummings, Kevin J, and Matthew R Hodges. “The serotonergic system and the control of breathing during development.” *Respiratory physiology & neurobiology* vol. 270 (2019): 103255. doi:10.1016/j.resp.2019.103255
57. Humeres C, Shinde AV, Hanna A, Alex L, Hernández SC, Li R, Chen B, Conway SJ, Frangogiannis NG. Smad7 effects on TGF-β and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure. J Clin Invest. 2022 Feb 1;132(3):e146926. doi: 10.1172/JCI146926. PMID: 34905511; PMCID: PMC8803336.
58. Ou Y, Liao C, Li H, Yu G. LncRNA SOX2OT/Smad3 feedback loop promotes myocardial fibrosis in heart failure. IUBMB Life. 2020 Nov;72(11):2469-2480. doi: 10.1002/iub.2375. Epub 2020 Sep 21. PMID: 32959533.
59. Hanna A, Humeres C, Frangogiannis NG. The role of Smad signaling cascades in cardiac fibrosis. Cell Signal. 2021 Jan;77:109826. doi: 10.1016/j.cellsig.2020.109826. Epub 2020 Nov 5. PMID: 33160018; PMCID: PMC7727442.
60. Loeys BL, Dietz HC. Loeys-Dietz Syndrome. 2008 Feb 28 [updated 2018 Mar 1]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 20301312.
61. Engström K, Vánky F, Rehnberg M, Trinks C, Jonasson J, Green A, Gunnarsson C. Novel SMAD3 p.Arg386Thr genetic variant co-segregating with thoracic aortic aneurysm and dissection. Mol Genet Genomic Med. 2020 Apr;8(4):e1089. doi: 10.1002/mgg3.1089. Epub 2020 Feb 5. PMID: 32022471; PMCID: PMC7196476.
62. Kalume F. Sudden unexpected death in Dravet syndrome: respiratory and other physiological dysfunctions. Respir Physiol Neurobiol. 2013 Nov 1;189(2):324-8. doi: 10.1016/j.resp.2013.06.026. Epub 2013 Jul 9. PMID: 23850567; PMCID: PMC7213775.
63. Hammer MF, Xia M, Schreiber JM. SCN8A-Related Epilepsy and/or Neurodevelopmental Disorders. 2016 Aug 25 [Updated 2023 Apr 6]. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK379665/
64. Sutphin BS, Boczek NJ, Barajas-Martínez H, Hu D, Ye D, Tester DJ, Antzelevitch C, Ackerman MJ. Molecular and Functional Characterization of Rare CACNA1C Variants in Sudden Unexplained Death in the Young. Congenit Heart Dis. 2016 Dec;11(6):683-692. doi: 10.1111/chd.12371. Epub 2016 May 24. PMID: 27218670.
65. Farrugia A, Rollet K, Sinniger J, Brun S, Spenle C, Ludes B, Taleb O, Mensah-Nyagan AG. H1153Y-*KCNH2* Mutation Identified in a Sudden Arrhythmic Death Syndrome Case Alters Channel Gating. Int J Mol Sci. 2021 Aug 26;22(17):9235. doi: 10.3390/ijms22179235. PMID: 34502138; PMCID: PMC8431075.
66. Toye JM, Lemire EG, Baerg KL. Perinatal and childhood morbidity and mortality in congenital analbuminemia. Paediatr Child Health. 2012 Jun;17(6):e20-3. PMID: 23730173; PMCID: PMC3380755.
67. Russo V, Melillo E, Papa AA, Rago A, Chamberland C, Nigro G. Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers. Cardiol Res Pract. 2019 Nov 30;2019:9319832. doi: 10.1155/2019/9319832. PMID: 31885907; PMCID: PMC6914907.
68. Blix AS. A possible cause of Sudden Infant Death Syndrome. Med Hypotheses. 2020 Mar;136:109520. doi: 10.1016/j.mehy.2019.109520. Epub 2019 Dec 9. PMID: 31855683.
69. Oski FA. Clinical implications of the oxyhemoglobin dissociation curve in the neonatal period. Crit Care Med. 1979 Sep;7(9):412-8. doi: 10.1097/00003246-197909000-00013. PMID: 38060.
70. Ramirez S, Allen T, Villagracia L, Chae Y, Ramirez JM, Rubens DD. Inner ear lesion and the differential roles of hypoxia and hypercarbia in triggering active movements: Potential implication for the Sudden Infant Death

Syndrome. Neuroscience. 2016 Nov 19;337:9-16. doi: 10.1016/j.neuroscience.2016.08.054. Epub 2016 Sep 12. PMID: 27634772.
71. Rubens DD, Vohr BR, Tucker R, O'Neil CA, Chung W. Newborn oto-acoustic emission hearing screening tests: preliminary evidence for a marker of susceptibility to SIDS. Early Hum Dev. 2008 Apr;84(4):225-9. doi: 10.1016/j.earlhumdev.2007.06.001. Epub 2007 Jul 5. PMID: 17614220.
72. Garcia AJ 3rd, Zanella S, Dashevskiy T, Khan SA, Khuu MA, Prabhakar NR, Ramirez JM. Chronic Intermittent Hypoxia Alters Local Respiratory Circuit Function at the Level of the preBötzinger Complex. Front Neurosci. 2016 Feb 4;10:4. doi: 10.3389/fnins.2016.00004. PMID: 26869872; PMCID: PMC4740384.
73. Gauda EB, Master Z. Contribution of relative leptin and adiponectin deficiencies in premature infants to chronic intermittent hypoxia: Exploring a new hypothesis. Respir Physiol Neurobiol. 2018 Oct;256:119-127. doi: 10.1016/j.resp.2017.12.003. Epub 2017 Dec 13. PMID: 29246449.
74. Poulsen JP, Rognum TO, Hauge S, Oyasaeter S, Saugstad OD. Post-mortem concentrations of hypoxanthine in the vitreous humor--a comparison between babies with severe respiratory failure, congenital abnormalities of the heart, and victims of sudden infant death syndrome. J Perinat Med. 1993;21(2):153-63. doi: 10.1515/jpme.1993.21.2.153. PMID: 8515358.
75. Stoltenberg L, Rootwelt T, Oyasaeter S, Rognum TO, Saugstad OD. Hypoxanthine, xanthine, and uric acid concentrations in plasma, cerebrospinal fluid, vitreous humor, and urine in piglets subjected to intermittent versus continuous hypoxemia. Pediatr Res. 1993 Dec;34(6):767-71. doi: 10.1203/00006450-199312000-00013. PMID: 8108190.
76. Rognum TO, Saugstad OD. Hypoxanthine levels in vitreous humor: evidence of hypoxia in most infants who died of sudden infant death syndrome. Pediatrics. 1991 Mar;87(3):306-10. PMID: 1796934.
77. Opdal SH, Rognum TO. The sudden infant death syndrome gene: does it exist? Pediatrics. 2004 Oct;114(4):e506-12. doi: 10.1542/peds.2004-0683. PMID: 15466077.
78. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, Griffin JH, Zlokovic BV. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron. 2004 Feb 19;41(4):563-72. doi: 10.1016/s0896-6273(04)00019-4. PMID: 14980205.
79. Ambrose N, Rodriguez M, Waters KA, Machaalani R. Cell death in the human infant central nervous system and in sudden infant death syndrome (SIDS). Apoptosis. 2019 Feb;24(1-2):46-61. doi: 10.1007/s10495-018-1509-0. PMID: 30600425.
80. Pinzón Martín S, Seeberger PH, Varón Silva D. Mucins and Pathogenic Mucin-Like Molecules Are Immunomodulators During Infection and Targets for Diagnostics and Vaccines. Front Chem. 2019 Oct 22;7:710. doi: 10.3389/fchem.2019.00710. Erratum in: Front Chem. 2019 Dec 05;7:846. PMID: 31696111; PMCID: PMC6817596.
81. Haynes RL, Trachtenberg F, Darnall R, Haas EA, Goldstein RD, Mena OJ, Krous HF, Kinney HC. Altered 5-HT2A/C receptor binding in the medulla oblongata in the sudden infant death syndrome (SIDS): Part I. Tissue-based evidence for serotonin receptor signaling abnormalities in cardiorespiratory- and arousal-related circuits. J Neuropathol Exp Neurol. 2023 May 25;82(6):467-482. doi: 10.1093/jnen/nlad030. PMID: 37226597; PMCID: PMC10209647.

Table 1. Cohort Characteristics

Demographics	Number of Cases	Proportion
Ethnicity		
Northern European	73	50.34%
African	63	43.45%
Hispanic	3	2.07%
American Indian	2	1.38%
Not specified	4	2.76%
Sex		
Male	79	54.48%
Female	66	45.52%
Age at Death		
< 60 days	39	26.90%
60 – 180 days	91	62.76%
180 – 365 days	12	8.28%
Unknown	3	2.07%
Gestational Age		
< 34 weeks	12	8.28%
34 – 36 weeks	16	11.03%
> 37 weeks	43	29.66%
Not specified	74	51.03%
Multiple Birth		
Singlet	135	93.10%
Twin	10	6.90%
Triplet	1	0.69%
Mild Illness at or Near Time of Death		
Congestion	8	5.52%
Mild cold symptoms	6	4.14%
Upper respiratory Infection	4	2.76%
Unspecified viral illness	2	1.38%
Bronchitis	1	0.69%
Bronchopneumonia	1	0.69%
Colic	1	0.69%
Cough	1	0.69%
Encephalitis	1	0.69%
Eye infection	1	0.69%
Fever	1	0.69%
Hypoglycemia and Hypothermia	1	0.69%
Listless	1	0.69%
Otitis	1	0.69%
Reflux	1	0.69%
Respiratory Distress Syndrome (prematurity)	1	0.69%
Respiratory Syncytial Virus (RSV)	1	0.69%
Unspecified bacterial illness	1	0.69%
Unspecified illness	1	0.69%

Vomitting	1	0.69%
Total	36	24.83%
Health Conditions		
Endocrine	7	4.83%
Respiratory	9	6.21%
Metabolic	4	2.76%
Cardiac	3	2.07%
Blood (Sickle cell)	1	0.69%
Total	24	16.55%
Autopsy Findings		
Lungs	27	18.62%
Heart	13	8.97%
Brain	8	5.52%
Kidneys	8	5.52%
Adrenal glands	7	4.83%
Liver	7	4.83%
Spleen	6	4.14%
Thymus	6	4.14%
Drug Exposures		
Cigarettes and cannabis	1	0.69%
Cigarettes, alcohol and other drugs, no opioids	1	0.69%
Cigarettes, alcohol and other drugs, including opioids	2	1.38%
Cigarettes and cocaine	1	0.69%
Cocaine alone	1	0.69%
Cocaine and opioids	1	0.69%
Opioids alone	2	1.38%
Cannabis alone	1	0.69%
Total	10	6.90%
Toxicology Results - Drugs		
Caffeine	1	0.69%
Benzodiazepine and midazolam	1	0.69%
Total	2	1.38%
Position Found		
Prone	40	27.59%
Supine	13	8.97%
Side	5	3.45%
Not specified	87	60.00%
Co-Sleeping Status		
Co-Sleeping	41	28.28%
Sleeping alone	65	44.83%
Not specified	39	26.90%
Sleeping Surface		
Bed/Mattress	35	24.14%
Crib	14	9.66%
Playpen/Portable crib	7	4.83%
Bassinette	4	2.76%

Sofa	4	2.76%
Being held	3	2.07%
Nursing pillow	2	1.38%
Bouncy seat	1	0.69%
Floor	1	0.69%
Sleeping bag	1	0.69%
Not specified	73	50.34%

Table 1. Cohort demographics as reported by parents, death scene investigators, MEs.

Table 2. ROS Pathway Variants

Gene	Variant Information	Allele Frequency (AF) in gnomAD	Number of Cases	Molecular Consequence	Previously Associated Condition (ClinVar)
AAGAB	Associated OMIM Conditions for the *AAGAB* variant below: Palmoplantar keratoderma punctate type 1A, AD, OMIM:148600				
	NC_000015.9:g.67528398G>A NM_024666.5(AAGAB):c.370C>T (p.Arg124*)	0.00003120 (NE), 0.00002509 (Total AF)	1	Stop gained	Palmoplantar keratoderma punctate type 1A, P
ATM	Associated OMIM Conditions for all *ATM* variants below: Hereditary cancer predisposing syndrome, AD, OMIM:114480 Ataxia-telangiectasia syndrome, AR, OMIM:208900				
	NC_000011.9:g.108143447A>G	Not found (NE, Total AF)	1	Splice acceptor	Hereditary cancer predisposing syndrome, P Ataxia-telangiectasia syndrome, P
	NC_000011.9:g.108100002C>A NM_000051.4(ATM):c.283C>A (p.Gln95Lys)	Not found (A) 0.0001240 (Total AF)	1	Missense	Hereditary cancer predisposing syndrome, LB/VUS Ataxia-telangiectasia syndrome, LB/VUS
	NC_000011.9:g.108172382G>C NM_000051.4(ATM):c.5185G>C (p.Val1729Leu)	0.00004006 (A) 0.0001026 (Total AF)	1	Missense	Hereditary cancer predisposing syndrome, LB/VUS Ataxia-telangiectasia syndrome, LB/VUS
	NC_000011.9:g.108178678T>A NM_001351834.2(ATM):c.5729T>A (p.Leu1910His)	Not found (NE, Total AF)	1	Missense	Not previously reported for this substitution Leu1910Pro at this location: Ataxia-telangiectasia syndrome, VUS
	NC_000011.9:g.108198447G>A NM_000051.4:c.7051G>A (p.Glu2351Lys)	Not found (A, Total AF)	1	Missense	Hereditary cancer predisposing syndrome, VUS
	NC_000011.9:g.108199766A>G NM_000051.4(ATM):c.7108A>G (p.Asn2370Asp)	Not found (AI/other) 0.00001759 (NE) 0.000007957 (Total AF)	2	Missense	Hereditary cancer predisposing syndrome, VUS Ataxia-telangiectasia syndrome, VUS
BRCA1	Associated OMIM Conditions for both *BRCA1* variants below: Breast-ovarian cancer, familial, susceptibility to, AD, OMIM:604370 Fanconi anemia, AR, OMIM:617883 Pancreatic cancer, susceptibility to, 4, AD, OMIM:614320				
	NC_000017.10:g.41244546del NM_007294.4(BRCA1):c.3005del (p.Asn1002fs)	Not Found (A) 0.000003987 (Total AF)	1	Frameshift	Hereditary cancer-predisposing syndrome, P
	NC_000017.10:g.41246584C>G NM_007294.4(BRCA1):c.964G>C (p.Ala322Pro)	0.00001759 (NE) 0.000007956 (Total AF)	1	Missense	Hereditary cancer-predisposing syndrome, LB/VUS Breast-ovarian cancer, familial, susceptibility to, LB/VUS
CFTR	Associated OMIM Conditions for all *CFTR* variants below: Cystic fibrosis, AR, OMIM:219700 Bronchiectasis with or without elevated sweat chloride 1, modifier of, AD, OMIM:211400 Congenital bilateral absence of vas deferens, AR, OMIM:277180 Pancreatitis, chronic, susceptibility to, AD, OMIM:167800				
	NC_000007.13:g.117232712G>A NM_000492.4(CFTR):c.2490+1G>A	Not Found (A) 0.00002149 (NE) 0.00001050 (Total AF)	2	Splice donor	Cystic fibrosis, P *CFTR*-related disorders, P

	NC_000007.13:g.117170992del NM_000492.4(CFTR):c.313del (p.Ile105fs)	0.00006153 (A) 0.000003982 (Total AF)	1	Frameshift	Cystic fibrosis, P Congenital bilateral aplasia of vas deferens from *CFTR* mutation, P *CFTR*-related disorders, P
	NC_000007.13:g.117149200A>G NM_000492.4(CFTR):c.273+4A>G	0.0002405 (A) 0.00002129 (Total AF)	1	Splice region	Cystic fibrosis, VUS *CFTR*-related disorders, P/VUS
	NC_000007.13:g.117188691dup NM_000492.4(CFTR):c.451C>A (p.Gln151Lys)	Not found (A) 0.000007205 (Total AF)	1	Splice region	Cystic fibrosis, VUS *CFTR*-related disorders, VUS
	NC_000007.13:g.117232712G>A NM_000492.4(CFTR):c.2490+1G>A	Not found (A) 0.00002149 (NE) 0.0000105 (Total AF)	2	Splice region	Cystic fibrosis, P CFTR-related disorders, P
COL7A1	Associated OMIM Conditions for all *COL7A1* variants below: Epidermolysis bullosa dystrophica/inversa AR, OMIM:226600 Toenail dystrophy, isolated, AD, OMIM:607523 Epidermolysis bullosa dystrophica, Bart type, AD, OMIM:132000 Transient bullous of the newborn, AD/AR, OMIM:131705 Epidermolysis bullosa dystrophica, AD, OMIM:131750 Epidermolysis bullosa pruriginosa, AD/AR, OMIM:604129 Epidermolysis bullosa, pretibial, OMIM:131850				
	NC_000003.11:g.48610345G>A NM_000094.4(COL7A1):c.6781C>T (p.Arg2261Ter)	0.00000882 (NE) 0.000007968 (Total AF)	1	Stop gained	Epidermolysis bullosa dystrophica/inversa, P
	NC_000003.11:g.48611166G>A	Not found (NE, Total AF)	1	Splice region	Not previously reported
	NC_000003.11:g.48615751C>T	0.000007763 (NE) 0.00002479 (Total AF)	1	Splice region	Not previously reported
	NC_000003.11:g.48629363C>T NM_000094.4(COL7A1):c.1325G>A (p.Arg442His)	Not found (AI/other) 0.0001556 (Total AF)	1	Missense	Not provided, VUS
ITGB3	Associated conditions in OMIM for the *ITGB3* variant below: Glanzmann thrombasthenia 1, AD, OMIM:273800 Platelet-type bleeding disorder 16, AD, OMIM:187800 Myocardial infarction, susceptibility to, Inheritance mode not given, OMIM:608446				
	NC_000017.11:g.47307584C>T NM_000212.3(ITGB3):c.2248C>T (p.Arg750Ter)	0.0006008 (A) 0.00005657 (Total AF)	1	Stop gained	Glanzmann thrombasthenia, 1 and 2, P Platelet-type bleeding disorder 16, P
LAMB3	Associated conditions in OMIM for the *LAMB3* variant below: Amelogenesis imperfecta, type IA, AD, OMIM:104530 Epidermolysis bullosa junctional Herlitz type, AR, OMIM:226700 Epidermolysis bullosa junctional non-Herlitz type, AR, OMIM:226650				
	NC_000001.10:g.209801424G>A NM_000228.3(LAMB3):c.1244C>T (p.Pro415Leu)	0.00002843 (NE) 0.00003406 (Total AF)	1	Missense	Not previously reported
SMAD3	Associated conditions in OMIM for the *SMAD3* variant below: Loeys-Dietz syndrome 3, AD, OMIM: 613795				
	NC_000015.9:g.67457303C>T NM_005902.4(SMAD3):c.277C>T (p.Arg93Ter)	0.00001758 (NE) 0.000007955 (Total AF)	1	Stop gained	Familial thoracic aortic aneurysm and aortic dissection, P Not provided, LP

Variants in genes involved in the ROS pathway and their associated conditions in ClinVar and OMIM. A=African/African American; AD=Autosomal Dominant; AF=Allele Frequency; AI=American Indian; AR=Autosomal Recessive; B=Benign; Hisp=Hispanic; LB=Likely Benign; LP=Likely Pathogenic; NE=Northern European; P=Pathogenic; VUS = Variant of Uncertain Significance;

Table 3. Variants in genes related to SUID found in other studies

Gene	Variant Information	Allele Frequency (AF) in gnomAD	Number of Cases	Molecular Consequence	Previously Associated Condition (ClinVar)
Cardiac Genes					
ABCC9	Associated OMIM conditions for the *ABCC9* variant below: Hypertrichotic osteochondrodysplasia, AD, OMIM:239850 Atrial fibrillation, familial 12, AD, OMIM:614050 Cardiomyopathy dilated, 1O, AD, ClinVar (VUS), OMIM:608569				
	NC_000012.11:g.21981893G>A NM_020297.4:(ABBC9)c.3668C>T (p.Thr1223Met)	0.0000465 (NE) 0.00003537 (Total AF)	1	Missense	Not Specified, VUS Cardiomyopathy dilated, 1O, VUS
ACTN2	Associated OMIM conditions for the *ACTN2* variant below: Myopathy, distal, 6, adult onset, AD, OMIM:618655; Cardiomyopathy, dilated, 1AA, with or without LVNC, AD, OMIM:612158; Cardiomyopathy, hypertrophic, 23, with or without LVNC, AD, OMIM:612158; Congenital myopathy 8, AD, OMIM:618654;				
	NC_000001.10:g.236883420A>G NM_001103.4(ACTN2):c.377A>G (p.Asn126Ser)	Not found (A, Total AF)	1	Missense	Not previously reported
AKAP9	Associated OMIM conditions for all *AKAP9* variants below: Long QT Syndrome, AD, OMIM:611820				
	NC_000007.13(AKAP9):g.91630931C>T NM_005751.5:c.1700C>T (p.Thr567Ile)	0.00002647 (NE) 0.00001197 (Total AF)	1	Missense	Long QT Syndrome, VUS
	NC_000007.13(AKAP9):g.91699479C>G NM_005751.5:c.6466C>G (p.Leu2156Val)	Not found (NE, Total AF)	1	Missense	Not previously reported
	NC_000007.13(AKAP9):g.91732118dup NM_005751.5(AKAP9):c.11308dup (p.Arg3770LysfsTer28)	Not found (A, Total AF)	1	Frameshift	Not previously reported
AKAP10	Associated OMIM conditions for the *AKAP10* variant below: Cardiac Conduction Effect, AD, OMIM:115080;				
	NC_000017.10:g.19844264G>A NM_007202.4(AKAP10):c.1121C>T (p.Thr374Ile)	Not found (A, Total AF)	1	Missense	Not previously reported
ANK2	Associated OMIM conditions for all *ANK2* variants below: Cardiac arrhythmia, ankyrin-B-related, AD, OMIM: 600919 Long QT Syndrome 4, AD, OMIM: 600919				
	NC_000004.11:g.114199044G>A NM_001148.6(ANK2):c.1735G>A (p.Ala579Thr)	0.000008807 (NE) 0.00000398 (Total AF)	1	Missense	Not previously reported
	NNE_000004.11:g.114267060G>A NM_001148.6(ANK2):NE.4253G>A (p.Arg1418His)	0.00001762 (NE) 0.000007963 (Total AF)	1	Missense	Not previously reported
	NC_000004.11:g.114280149C>T NM_001148.6(ANK2):c.10375C>T (p.Pro3459Ser)	0.00002337 (NE) 0.00001067 (Total AF)	1	Missense	Long QT Syndrome, VUS Cardiovascular phenotype, VUS

	NC_000004.11:g.114294304A>G NM_001148.6(ANK2):c.11669A>G (p.Glu3890Gly)	Not found (NE) 0.000003981 (Total AF)	1	Missense	Not previously reported
BAG3	Associated OMIM conditions for both *BAG3* variants below: Cardiomyopathy, dilated, 1HH, AD, OMIM:613881; Myopathy, myofibrillar, 6, AD, OMIM:612954;				
	NC_000010.10:g.121411282C>T NM_004281.4(BAG3):c.95C>T (p.Pro32Leu)	Not found (A, NE, Total AF)	1	Missense	Not provided, VUS Dilated cardiomyopathy 1HH, VUS Myofibrillar myopathy 6, VUS
	NC_000010.10:g.121436354G>A NM_004281.4(BAG3):c.1288G>A (p.Glu430Lys)	Not found (A, NE, Total AF)	1	Missense	Myofibrillar myopathy 6, VUS Dilated cardiomyopathy 1HH, VUS Cardiovascular phenotype, VUS
CACNA1C	Associated OMIM conditions for both *CACNA1C* variants below: Timothy Syndrome, AD, OMIM:601005 Long QT Syndrome, AD, OMIM:618447 Brugada Syndrome, AD, OMIM:611875				
	NC_000012.11:g.2702441C>G NM_000719.7(CACNA1C):c.2593C>G (p.Leu865Val)	Not found (NE) 0.000004023 (Total AF)	1	Missense	Long QT Syndrome, VUS
	NC_000012.11:g.2800148G>A NM_000719.7(CACNA1C):c.6200G>A (p.Cys2067Tyr)	Not found (NE) 0.000004472 (Total AF)	1	Missense	Not previously reported
CACNB2	Associated OMIM conditions for both *CACNB2* variants below: Brugada Syndrome 4, AD, OMIM:611876				
	NC_000010.10:g.18439811G>A	Not found (NE, Total AF)	1	Splice acceptor	Not previously reported
	NC_000010.10:g.18828300G>A NM_000724.4(CACNB2):c.1465G>A (p.Gly489Arg)	Not found (NE, Total AF)	1	Missense	Not previously reported
CALM2	Associated OMIM conditions for both *CALM2* variants below: Long QT syndrome 15, AD, OMIM:616249				
	NC_000002.11:g.47394863_47394867del	Not found (NE, Total AF)	2 (Cmp Het, Het)	Splice Region	Not previously reported
	NC_000002.11:g.47394853_47394867del	Not found (A, NE, Total AF)	2 (Cmp Het, Hom)	Splice Region	Not previously reported
CTNNA3	Associated OMIM conditions for the *CTNNA3* variant below: Arrhythmogenic right ventricular dysplasia, familial 13, AD, OMIM:615616;				
	NC_000010.10:g.67680324C>T NM_013266.4(CTNNA3):c.2452G>A (p.Val818Ile)	Not found (A, Total AF)	1	Missense	Not previously reported
DCHS1	Associated OMIM conditions for both *DCHS1* variants below: Mitral valve prolapse 2, AD, OMIM:607829 Van Maldergem syndrome 1, AR, OMIM:601390				
	NC_000011.9:g.6661424C>T NM_003737.4(DCHS1):c.1421G>A (p.Arg474His)	0.00003123 (NE) 0.0000178 (Total AF)	1	Missense	Not previously reported
	NC_000011.9:g.6661730G>A NM_003737.4(DCHS1):c.1115C>T (p.Ser372Phe)	Not found (NE, Total AF)	1	Missense	Not previously reported

DPP6	Associated OMIM conditions for the *DPP6* variant below: Mental retardation 33, AD, OMIM:616311; Ventricular fibrillation, paroxysmal familial 2, AD, OMIM:612956;				
	NC_000007.13:g.154672617T>C NM_001936.5(DPP6):c.1912T>C (p.Tyr638His)	Not found (A, Total AF)	1	Missense	Not previously reported
DSG2	Associated OMIM conditions for the *DSG2* variant below: Arrhythmogenic right ventricular dysplasia 10, AD, OMIM:610193 Cardiomyopathy dilated 1BB, AR, OMIM:612877;				
	NC_000018.9:g.29104714A>T NM_001943.5(DSG2):c.877A>T (p.Ile293Leu)	Not found (A) 0.00001068 (Total AF)	1	Missense	Arrhythmogenic right ventricular dysplasia 10, VUS Cardiovascular Phenotype, VUS Cardiomyopathy, VUS Not specified, LB/VUS
DSP	Associated OMIM conditions for all *DSP* variants below: Keratosis palmoplantaris striata II, AD, OMIM:612908 Arrhythmogenic right ventricular dysplasia 8, AD, OMIM:607450 Cardiomyopathy dilated with woolly hair and keratoderma, AR, OMIM:605676 Skin fragility-woolly hair syndrome, AR, OMIM:607655 Dilated cardiomyopathy with woolly hair keratoderma and tooth agenesis, AD, OMIM:615821 Epidermolysis bullosa lethal acantholytic, AR, OMIM:609638				
	NC_000006.11:g.7558461G>A NM_004415.4(DSP):c.386G>A (p.Arg129Gln)	0.00001759 (NE) 0.00001193 (Total AF)	1	Missense	Cardiomyopathy, VUS Not provided, VUS
	NC_000006.11:g.7572209G>A NM_004415.4:c.2038G>A (p.Glu680Lys)	Not found (NE, Total AF)	1	Missense	Arrhythmogenic cardiomyopathy with woolly hair and keratoderma, VUS Arrhythmogenic right ventricular dysplasia 8, VUS Cardiovascular phenotype, VUS
	NC_000006.11:g.7577256T>C NM_004415.4(DSP):c.2858T>C (p.Leu953Pro)	0.00002654 (NE) 0.000026544 (Total AF)	1	Missense	Cardiomyopathy, VUS Cardiovascular Phenotype, VUS Not provided, VUS
	NC_000006.11:g.7583856G>A NM_004415.4(DSP):c.6361G>A (p.Gly2121Arg)	8.796E-06 (NE) 0.000003978 (Total AF)	1	Missense	Arrhythmogenic cardiomyopathy with woolly hair and keratoderma, VUS Arrhythmogenic right ventricular dysplasia 8, VUS
	NC_000006.11:g.7585410C>T NM_004415.4(DSP):c.7915C>T (p.Arg2639Trp)	0.00003898 (Unk, Total AF)	1	Missense	Cardiomyopathy, VUS Arrhythmogenic cardiomyopathy with woolly hair and keratoderma, VUS Arrhythmogenic right ventricular dysplasia 8, VUS Not provided, VUS
FLNC	Associated OMIM conditions for the *FLNC* variant below: Cardiomyopathy, familial hypertrophic 26, AD, OMIM:617047; Myopathy myofibrillar 5, AD, OMIM:609524; Cardiomyopathy, familial restrictive 5, AD, OMIM:617047; Myopathy, distal 4, AD, OMIM:614065;				

	NC_000007.13:g.128482877C>T NM_001458.5(FLNC):c.2419C>T (p.Pro807Ser)	0.00002659 (NE) 0.00001205 (Total AF)	1	Missense	Not provided, VUS Cardiovascular phenotype, VUS Inborn genetic diseases, VUS Dilated Cardiomyopathy, DomiNot previously reportednt, VUS Hypertrophic cardiomyopathy 26, VUS Distal myopathy with posterior leg and anterior hand involvement, VUS Myofibrillar myopathy 5, VUS
FPGT-TNNI3	Associated OMIM conditions for the *FPGT-TNNI3* variant below: Cardiac conduction disease with or without dilated cardiomyopathy, AD, OMIM:616117;				
	NC_000001.10:g.75009665G>A NM_015978.3(TNNI3K):c.2507G>A (p.Ter836=extTer7)	Not found (Hisp, Total AF)	1	Stop gained	Not provided, VUS
GJA1	Associated OMIM conditions for both *GJA1* variants below: Erythrokeratodermia variabilis et progressiva 3, AD, OMIM:617525 Craniometaphyseal dysplasia, AR, OMIM:218400 Atrioventricular septal defect 3, AD, OMIM:600309 Oculodentodigital dysplasia, AD, OMIM:164200; AR, OMIM: 257850 Syndactyly type III, AD, OMIM: 186100 Hypoplastic left heart syndrome 1, AR, OMIM: 241550; Palmoplantar keratoderma with congenital alopecia, AD, OMIM:104100;				
	NC_000006.11:g.121768451G>A NM_000165.5(GJA1):c.458G>A (p.Arg153Gln)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000006.11:g.121768843C>T NM_000165.5(GJA1):c.850C>T (p.Pro284Ser)	Not found (NE, Total AF)	1	Missense	Not previously reported
HCN4	Associated OMIM conditions for the *HCN4* variant below: Brugada syndrome 8, AD, OMIM:613123; Sick sinus syndrome 2, AD, OMIM:163800;				
	NC_000015.9:g.73615240A>G NM_005477.3(HCN4):c.3194T>C (p.Val1065Ala)	Not found (A, Total AF)	1	Missense	Brugada syndrome 8, VUS
JPH2	Associated OMIM conditions for the *JPH2* variant below: Cardiomyopathy hypertrophic 17, AD, OMIM:613873;				
	NC_000020.10:g.42788880G>C NM_020433.5(JPH2):c.547C>G (p.Pro183Ala)	Not found (A, Total AF)	1	Missense	Hypertrophic cardiomyopathy, VUS Hypertrophic cardiomyopathy 17, VUS Cardiomyopathy, Dilated, 2E, VUS Cardiovascular phenotype, VUS
KCND2	No Associated OMIM conditions for the *KCND2* variant below.				
	NC_000007.13:g.120373105C>T NM_012281.3(KCND2):c.1264C>T (p.Arg422*)	Not found (NE, Total AF)	1	Stop gained	Not previously reported
KCNH2	Associated OMIM conditions for all *KCNH2* variants below: Long QT syndrome 2, acquired susceptibility to, AD, OMIM:613688 Long QT syndrome 2, AD, OMIM:613688 Short QT syndrome 1, mode of inheritance not given, OMIM:609620				
	NC_000007.13:g.150655492_150655500dup NM_000238.4(KCNH2):c.567_575dup (p.Gly192_Ala193insAlaProGly)	0.000003987 (Unk, Total AF)	1	In-frame insertion	Long QT syndrome, VUS Cardiovascular phenotype, VUS Not provided, VUS

LAMA4	Associated OMIM conditions for all *LAMA4* variants below: Cardiomyopathy, dilated 1JJ, AD, OMIM:615235				
	NC_000006.11:g.112441568C>T NM_002290.5(LAMA4):c.4562G>A (p.Arg1521His)	0.00002647 (NE) 0.00004784 (Total AF)	1	Missense	Cardiomyopathy, dilated 1JJ, VUS Cardiovascular phenotype, VUS Not provided, VUS
	NC_000006.11:g.112441622T>C NM_002290.5(LAMA4):c.4508A>G (p.Tyr1503Cys)	Not found (NE, total AF)	1	Missense	Not previously reported
	NC_000006.11:g.112454633A>T NM_002290.5(LAMA4):c.3593T>A (p.Phe1198Tyr)	Not found (NE, total AF)	1	Missense	Not previously reported
LDB3	Associated OMIM conditions for both *LDB3* variants below: Cardiomyopathy hypertrophic 24, AD, OMIM:601493 Cardiomyopathy dilated 1C with or without LVNC, AD, OMIM:601493 Myopathy, myofibrillar 4, AD, OMIM:609452 Left ventricular noncompaction 3, AD, OMIM:601493				
	NC_000010.10:g.88446961G>A NM_001080114.2(LDB3):c.480G>A (p.Met160Ile)	Not found (NE, Total AF)	1	Missense	Myofibrillar myopathy 4, VUS
	NC_000010.10:G:Ag.88459055G>A NM_001080115.2(LDB3):c.917G>A (p.Arg306His)	0.00001563 (NE) 0.00001428 (Total AF)	1	Missense	Myofibrillar myopathy 4, VUS
MYBPC3	Associated OMIM conditions for both *MYBPC3* variants below: Cardiomyopathy hypertrophic, AR/AD, OMIM:115197 Cardiomyopathy dilated 1MM, AD, OMIM:615396 Left ventricular noncompaction 10, AD, OMIM:615396				
	NC_000011.9:g.47353764C>T NM_000256.3(MYBPC3):c.3673G>A (p.Ala1225Thr)	Not found (NE) 0.000004013 (Total AF)	1	Missense	Not provided, VUS Cardiomyopathy, VUS Hypertrophic cardiomyopathy, VUS
	NC_000011.9:g.47365086C>T NM_000256.3(MYBPC3):c.1180G>A (p.Val394Ile)	0.000009127 (NE) 0.000004138 (Total AF)	1	Missense	Hypertrophic cardiomyopathy, VUS
MYH6	Associated OMIM conditions for both *MYH6* variants below: Atrial septal defect 3, Inheritance mode not given, OMIM:614089 Cardiomyopathy, hypertrophic 14, AD, OMIM:613251 Sick sinus syndrome 3, mode of inheritance not given, OMIM:614090 Cardiomyopathy dilated 1EE, AD, OMIM:613252				
	NC_000014.8:g.23852520C>T NM_002471.4(MYH6):c.5575G>A (p.Asp1859Asn)	0.00001644 (NE) 0.000007666 (Total AF)	1	Missense	Hypertrophic cardiomyopathy 14, VUS Cardiovascular Phenotype, VUS Not provided, VUS
	NC_000014.8:g.23855760C>T NM_002471.4(MYH6):c.4723G>A (p.Glu1575Lys)	0.000007745 (NE) 0.00002476 (Total AF)	1	Missense	Hypertrophic cardiomyopathy 14, VUS Cardiovascular Phenotype, VUS
MYH11	Associated OMIM conditions for all *MYH11* variants below: Aortic aneurysm, familial thoracic 4, AD, OMIM:132900				
	NC_000016.9:g.15797934G>A NM_002474.3(MYH11):c.5833C>T (p.Arg1945Cys)	0.00000879 (NE) 0.000007953 (Total AF)	1	Missense	Familial thoracic aortic aneurysm and aortic dissection, VUS Not provided, VUS
	NC_000016.9:g.15815461T>G NM_002474.3(MYH11):c.4396A>C (p.Lys1466Gln)	0.000008791 (NE) 0.000003977 (Total AF)	1	Missense	Aortic aneurysm, familial thoracic 4, VUS Familial thoracic aortic aneurysm and aortic dissection, VUS
	NC_000016.9:g.15847245C>T	Not Found (NE, Total AF)	1	Splice Region	Familial thoracic aortic aneurysm and aortic dissection, LB

	NC_000016.9:g.15850194G>C	Not Found (NE) 0.0000354 (Total AF)	1	Splice Region	Aortic aneurysm, familial thoracic 4, VUS Cardiovascular phenotype, VUS Familial thoracic aortic aneurysm and aortic dissection, VUS
	NC_000016.9:g.15857704C>T NM_002474.3(MYH11):c.1078G>A (p.Val360Ile)	0.00001551 (NE) 0.00005308 (Total AF)	1	Missense	Aortic aneurysm, familial thoracic 4, VUS Familial thoracic aortic aneurysm and aortic dissection, LB/VUS Inborn genetic diseases, VUS
MYLK	Associated OMIM conditions for both *MYLK* variants below: Aortic aneurysm, familial thoracic 7, AD, OMIM:613780 Megacystis-microcolon-intestinal hypoperistalsis syndrome, AR, OMIM:249210				
	NC_000003.11:g.123444927T>C	0.00002663 (NE) 0.000012 (Total AF)	1	Splice Acceptor	Not provided, VUS/LP
	NC_000003.11:g.123457763G>A NM_053025.4(MYLK):c.569C>T (p.Pro190Leu)	0.00002365 (NE) 0.00006481 (Total AF)	1	Missense	Aortic aneurysm, familial thoracic 7, VUS Familial thoracic aortic aneurysm and aortic dissection, VUS
MYPN	Associated OMIM conditions for the *MYPN* variant below: Cardiomyopathy, dilated 1KK, AD, OMIM:615248 Cardiomyopathy familial restrictive, 4, AD, OMIM:615248 Nemaline myopathy 11, AR, OMIM:617336 Cardiomyopathy, hypertrophic 22, AD, OMIM: 615248				
	NC_000010.10:g.69881260C>G NM_032578.4(MYPN):c.65C>G (p.Ala22Gly)	Not found (NE) 0.0001385 (AI) 0.0002546 (Total AF)	2	Missense	Dilated cardiomyopathy 1KK, LB Cardiovascular Phenotype, LB Not provided, VUS
NOTCH1	Associated OMIM conditions for both *NOTCH1* variants below: Aortic valve disease 1, AD, OMIM:109730 Adams-Oliver syndrome 5, AD, OMIM: 616028				
	NC_000009.11:g.139400291C>T NM_017617.5(NOTCH1):c.4057G>A (p.Gly1353Ser)	0.00004519 (A) 0.00001583 (Total AF)	1	Missense	Not provided, VUS
	NC_000009.11:g.139417452C>T NM_017617.5(NOTCH1):c.592G>A (p.Glu198Lys)	Not found (NE) 0.00001023 (Total AF)	1	Missense	Not previously reported
PRDM16	Associated OMIM conditions for the *PRDM16* variant below: Left ventricular noncompaction 8, AD, OMIM:615373 Cardiomyopathy, dilated, 1LL, AD, OMIM:615373				
	NC_000001.10:g.3347438C>T NM_022114.4(PRDM16):c.3287C>T (p.Ala1096Val)	Not found (A) 0.00002836 (Total AF)	1	Missense	Left ventricular noncompaction 8, VUS Not provided, VUS
RANGRF; SLC25A35	No Associated OMIM conditions for the RANGRF/SLC25A35 variant below.				
	NC_000017.10:g.8192285C>G NM_016492.5(RANGRF):c.89C>G (p.Pro30Arg)	Not found (A) 0.000003984 (Total AF)	1	Missense	Not previously reported
RYR2	Associated OMIM conditions for all *RYR2* variants below: Ventricular tachycardia catecholaminergic polymorphic 1, AD, OMIM:604772 Arrhythmogenic right ventricular dysplasia 2, AD, OMIM:600996				
	NC_000001.10:g.237496932A>T NM_001035.3(RYR2):c.2440C>A (p.Leu814Ile)	Not found (NE, Total AF)	1	Splice region	Not previously reported

	NC_000001.10:g.237666632C>A NM_001035.3(RYR2):c.2440C>A (p.Leu814Ile)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000001.10:g.237670022C>A NM_001035.3(RYR2):c.2626C>A (p.Pro876Thr)	Not found (NE, Total AF)	1	Missense	Not previously reported
	NC_000001.10:g.237870348G>A NM_001035.3(RYR2):c.9680G>A (p.Arg3227His)	Not found (A) 0.00000713 (Total AF)	1	Missense	Catecholaminergic polymorphic ventricular tachycardia, VUS Cardiovascular phenotype, VUS
	NC_000001.10:g.237921044A>G NM_001035.3(RYR2):c.11293A>G (p.Ile3765Val)	0.00004132 (A) 0.000007134 (Total AF)	1	Missense	Catecholaminergic polymorphic ventricular tachycardia, VUS Cardiovascular phenotype, VUS
	NC_000001.10:g.237957284G>A NM_001035.3(RYR2):c.13900G>A (p.Val4634Ile)	0.0000143 (Unk, Total AF)	1	Missense	Arrhythmogenic right ventricular dysplasia 2, VUS
SCN1B	Associated OMIM conditions for the *SCN1B* variant below: Atrial fibrillation familial 13, AD, OMIM:615377; Developmental and epileptic encephalopathy 52, AR, OMIM:617350; Cardiac conduction defect nonspecific generalized with febrile seizures plus type 1, AD, OMIM:604233; Brugada syndrome 5, AD, OMIM:612838;				
	NC_000019.9:g.35524842G>A NM_199037.5(SCN1B):c.647G>A (p.Gly216Asp)	Not found (A, Total AF)	1	Missense	Brugada syndrome 5, VUS Not specified, VUS
SCN3B	Associated OMIM conditions for the *SCN3B* variant below: Brugada syndrome 7, AD, OMIM:613120 Atrial fibrillation, familial 16, AD, OMIM:613120				
	NC_000011.9:g.123513271C>T NM_018400.4(SCN3B):c.328G>A (p.Val110Ile)	0.00003871 (NE) 0.0003111 (Total AF)	1	Missense	Death in Infancy, P Cardiomyopathy, LB Brugada syndrome 7, LB Cardiovascular phenotype, LB Not provided, LB, VUS
SCN5A	Associated OMIM conditions for the *SCN5A* variant below: Atrial fibrillation, familial 10, AD, OMIM:614022 Sick sinus syndrome 1, AD, OMIM: 608567 Sudden infant death syndrome, susceptibility to, AR, OMIM:272120 Ventricular fibrillation, familial 1, mode of inheritance not given, OMIM:603829 Long QT syndrome 3, AD, OMIM:603830 Heart block, nonprogressive, AD, OMIM:113900 Cardiomyopathy, dilated, 1E, AD, OMIM:601154 Brugada syndrome 1, AD, OMIM:601144 Heart block, progressive, type IA, AD, OMIM:113900				
	NC_000003.11:g.38591816A>T NM_000335.5(SCN5A):c.6044T>A (p.Val2015Glu)	Not found (NE, Total AF)	1	Missense	Not previously reported
SCN10A	Associated OMIM conditions for both *SCN10A* variants below: Episodic pain syndrome, familial 2; OMIM:615551				
	NC_000003.11:g.38770056C>T NM_006514.4(SCN10A):c.2617G>A (p.Val873Met)	0.00002761 (NE) 0.00001246 (Total AF)	1	Missense	Brugada Syndrome, VUS Not provided, VUS
	NC_000003.11:g.38770187C>T NM_006514.4(SCN10A):c.2486G>A (p.Arg829His)	0.000008803 (NE) 0.000007959 (Total AF)	1	Missense	Brugada Syndrome, VUS
SLMAP	No Associated OMIM conditions for the *SLMAP* variant below.				

	NC_000003.11:g.57882621A>G NM_007159.5(SLMAP):c.1361A>G (p.Asp454Gly)	0.000008848 (NE) 0.000004015 (Total AF)	1	Missense	Not previously reported
TGFB3	Associated OMIM conditions for the *TGFB3* variant below: Loeys-Dietz syndrome 5, AD, OMIM:615582; Arrhythmogenic right ventricular dysplasia 1, AD, OMIM:107970;				
	NC_000014.8:g.76431926G>A NM_003239.5(TGFB3):c.754+5C>T	Not found (NE, Total AF)	1	Splice Region	Rienhoff syndrome, VUS Not provided, LB Familial thoracic aortic aneurysm and aortic dissection, VUS
TMEM43	Associated OMIM conditions for the *TMEM43* variant below: Emery-Dreifuss muscular dystrophy 7, AD, OMIM:614302; Arrhythmogenic right ventricular dysplasia 5, AD, OMIM:604400;				
	NC_000003.11:g.14173126T>C NM_024334.3(TMEM43):c.344T>C (p.Leu115Pro)	0.0000264 (NE) 0.00001194 (Total AF)	1	Missense	Cardiovascular phenotype, VUS Not provided, VUS Cardiomyopathy, VUS Arrhythmogenic right ventricular dysplasia 5, VUS
TNNC1	Associated OMIM conditions for the *TNNC1* variant below: Cardiomyopathy hypertrophic 13, AD, OMIM:13243; Cardiomyopathy dilated 1Z, AD, OMIM:611879;				
	NC_000003.11:g.52486116G>A NM_003280.3(TNNC1):c.202+6C>T	Not found (A) 0.000003984 (Total AF)	1	Splice Region	Dilated cardiomyopathy 1Z, VUS Hypertrophic cardiomyopathy 13, VUS
TRDN	Associated OMIM conditions for both *TRDN* variants below: Ventricular tachycardia catecholaminergic polymorphic 5 with or without muscle weakness, AR, OMIM:615441				
	NC_000006.11:g.123869697dup NM_006073.4(TRDN):c.295dup	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000006.11:g.123869698C>T NM_006073.4(TRDN):c.292G>A (p.Glu98Lys)	Not found (A, Total AF)	1	Missense	Cardiovascular Phenotype, VUS
TRPM4	Associated OMIM conditions for the *TRPM4* variant below: Erythrokeratodermia veriabilis et progressiva 6, AD, OMIM:618531 Progressive familial heart block, type IB, AD, OMIM:604559				
	NC_000019.9:g.49671868_49671869insGAA NM_017636.4(TRPM4):c.671_672insGAA (p.Pro224_Leu225insAsn)	Not found (NE, Total AF)	1	Inframe insertion	Not previously reported
TTN	Associated OMIM conditions for all TTN variants below: Myopathy myofibrillar 9 with early respiratory failure, AD, OMIM:603689; Cardiomyopathy familial hypertrophic 9, AD, OMIM:613765; Muscular dystrophy limb-girdle autosomal recessive 10, AR, 608807; Cardiomyopathy dilated, 1G, OMIM:604145; Tibial muscular dystrophy, tardive, AD, OMIM:600334; Salih myopathy, AR, OMIM:611705;				
	NC_000002.11:g.179393283T>C NM_003319.4(TTN):c.80000A>G (p.Glu26667Gly)	Not found (NE, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179404843C>T NM_003319.4(TTN):c.70855G>A (p.Gly23619Ser)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179418773G>A NM_003319.4(TTN):c.61870C>T (p.Arg20624Cys)	Not found (A) 0.000008046 (Total AF)	1	Missense	Not provided, VUS

	NC_000002.11:g.179419446A>G NM_003319.4(TTN):c.61433T>C (p.Phe20478Ser)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179422192C>T NM_003319.4(TTN):c.60602G>A (p.Gly20201Asp)	Not found (Unk, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179422617A>G NM_003319.4(TTN):c.60269T>C (p.Val20090Ala)	Not found (NE, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179440747C>T NM_003319.4(TTN):c.42917G>A (p.Arg14306His)	Not found (NE) 0.00000805 (Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179463580G>T NM_003319.4(TTN):c.29662C>A (p.Leu9888Ile)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179479442C>G NM_003319.4(TTN):c.21604G>C (p.Gly7202Arg)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179604015T>C NM_003319.4(TTN):c.12856A>G (p.Lys4286Glu)	Not found (NE, Total AF)	1	Missense	Dilated cardiomyopathy 1G, VUS Autosomal recessive limb-girdle muscular dystrophy type 2J, VUS
	NC_000002.11:g.179613353C>A NM_133379.5(TTN):c.13774G>T (p.Glu4592*)	0.000008910 (NE) 0.000004007 (Total AF)	1	Stop gained	Not previously reported
	NC_000002.11:g.179636193C>T NM_003319.4(TTN):c.7723G>A (p.Ala2575Thr)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.179640399A>C NM_003319.4(TTN):c.6054T>G (p.Phe2018Leu)	0.00003553 (NE) 0.00001599 (Total AF)	1	Missense	Dilated cardiomyopathy 1G ,VUS Autosomal recessive limb-girdle muscular dystrophy type 2, VUS Not provided, VUS
Epilepsy Genes					
CACNA1H	Associated OMIM conditions for all *CACNA1H* variants below: Epilepsy, idiopathic generalized, susceptibility to, 6, OMIM:611942; Epilepsy, childhood absence, susceptibility to, 6, OMIM:611942; Hyperaldosteronism, familial, type IV, AD, OMIM:617027; Epilepsy, idiopathic generalized, susceptibility to, 1, AD, OMIM:600669;				
	NC_000016.9:g.1203949C>G NM_021098.3(CACNA1H):c.212C>G (p.Pro71Arg)	Not found (C, Total AF)	1	Missense	Idiopathic generalized epilepsy, VUS Hyperaldosteronism, familial, type IV, VUS Epilepsy, childhood absence, susceptibility to, 6, VUS
	NC_000016.9:g.1250576G>T NM_021098.3(CACNA1H):c.1119+5G>T	Not found (A, Total AF)	1	Splice region	Not previously reported
	NC_000016.9:g.1264987C>G NM_021098.3(CACNA1H):c.4945C>G (p.Leu1649Val)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000016.9:g.1270539_1270548del NM_021098.3(CACNA1H):c.6607_6616del (p.Ser2203ProfsTer11)	Not found (C, Total AF)	1	Frameshift	Not previously reported
CACNB4	Associated OMIM conditions for the *CACNB4* variant below: Epilepsy, idiopathic generalized, susceptibility to, 9, AD, OMIM:607682; Episodic ataxia, type 5, AD, OMIM:613855;				

	NC_000002.11:g.152695823G>T NM_000726.5(CACNB4):c.1373C>A (p.Ser458Tyr)	Not found (A) 0.00002010 (Total AF)	1	Missense	Idiopathic generalized epilepsy, VUS
CHD2	Associated OMIM conditions for the *CHD2* variant below: Developmental and epileptic encephalopathy 94, AD, OMIM:602119;				
	NC_000015.9:g.93567817C>A NM_001271.4(CHD2):c.5369C>A (p.Pro1790His)	Not found (A) 0.00001603 (Total AF)	1	Missense	Not previously reported
CLCN4	Associated OMIM conditions for the *CLCN4* variants below: Raynaud-Claes syndrome, X-linked dominant, OMIM:300114;				
	NC_000023.10:g.10181730C>T NM_001830.4(CLCN4):c.1586C>T (p.Thr529Ile)	Not found (A, Total AF)	1	Missense	Not previously reported
DNM1L	Associated OMIM conditions for the *DNM1L* variant below: Encephalopathy, lethal due to defective mitochondrial peroxisomal fission 1, AR,AD, OMIM:614388; Optic atrophy 5, AD, OMIM: 610708;				
	NC_000012.11:g.32871615A>C NM_005690.5(DNM1L):c.658A>C (p.Met220Leu)	Not found (A, Total AF)	1	Missense	Inborn genetic diseases, VUS
DYRK1A	Associated OMIM conditions for the *DYRK1A* variant below: Mental retardation 7, AD, OMIM:614104;				
	NC_000021.8:g.38850482G>C NM_001347721.2(DYRK1A):c.208-28G>C	0.0001231 (A) 0.000007971 (Total AF)	1	Splice Acceptor	DYRK1A-related intellectual disability syndrome, VUS Not provided, VUS
EFHC1	Associated OMIM conditionsn with the *EFHC1* variant below: Myoclonic epilepsy juvenile susceptibility to 1, AD, OMIM:254770; Epilepsy juvenile absence susceptibility to, AD, OMIM:607631;				
	NC_000006.11:g.52303214T>C NM_018100.4(EFHC1):c.398T>C (p.Val133Ala)	Not found (A, Total AF)	1	Missense	Not previously reported
GRIN1	Associated OMIM conditions with the *GRIN1* variant below: Urodevelopmental disorder with or without hyperkinetic movements and seizures, AR, OMIM:617820; Neurodevelopmental disorder with or without hyperkinetic movements and seizures, AD, OMIM:614254;				
	NC_000009.11:g.140056463A>G NM_000832.7(GRIN1):c.1555A>G (p.Ile519Val)	Not found (A, Total AF)	1	Missense	Not previously reported
GRIN2A	Associated OMIM conditions with the *GRIN2A* variant below: Epilepsy focal with speech disorder and with or without mental retardation, AD, OMIM:245570;				
	NC_000016.9:g.9858026C>G NM_000833.5(GRIN2A):c.212C>G (p.Ala71Gly)	Not found (A, Total AF)	1	Missense	Landau-Kleffner syndrome, VUS Not provided, VUS
GRIN2B	Associated OMIM conditions with the *GRIN2B* variant below: Developmental and epileptic encephalopathy 27, AD, OMIM:616139; Mental retardation, autosomal dominant 6, AD, OMIM:613970;				
	NC_000012.11:g.13761764G>C NM_000834.5(GRIN2B):c.1783C>G (p.Pro595Ala)	Not found (A) 0.000007967 (Total AF)	1	Missense	Not previously reported
KCNA2	Associated OMIM conditions for the *KCNMA1* variant below: Developmental and epileptic encephalopathy 32, AD, OMIM:616366;				
	NC_000001.10:g. NM_001204269.2(KCNA2):c.957dup (p.Asp320*)	Not found (C, Total AF)	1	Frameshift	Not previously reported

KCNMA1	Associated OMIM conditions related to both *KCNMA1* variants below: Liang-Wang syndrome, AD, OMIM:618729; Epilepsy idiopathic generalized susceptibility to 16, AD, OMIM:618596; Cerebellar atrophy and seizures, AR, OMIM:617643; Paroxysmal nonkinesigenic dyskinesia 3 with or without generalized epilepsy, AD, OMIM:609446;				
	NC_000010.10:g.78734333T>G NM_002247.4(KCNMA1):c.2093-4508A>C	Not found (A) 0.000006762 (Total AF)	1	Splice acceptor	Not previously reported
	NC_000010.10:g.78674702G>A NM_002247.4(KCNMA1):c.2834C>T (p.Thr945Ile)	Not found (Unk, Total AF)	1	Missense	Not previously reported
KCNQ3	Associated OMIM conditions for the *KCNQ3* variant below: Seizures benign neonatal 2, AD, OMIM:121201				
	NC_000008.10:g.133146633A>G NM_004519.4(KCNQ3):c.1703T>C (p.Ile568Thr)	Not found (A, Total AF)	1	Missense	Not previously reported
KCNT1	Associated OMIM conditions for the *KCNT1* variant below: Epilepsy nocturnal frontal lobe 5, AD, OMIM:615005; Developmental and epileptic encephalopathy 14, AD, OMIM:614959;				
	NC_000009.11:g.138671256G>A NM_020822.3(KCNT1):c.2781G>A (p.Met927Ile)	Not found (NE, Total AF)	1	Missense	Not previously reported
RANBP2	Associated OMIM conditions for the *RANBP2* variant below: Encephalopathy acute infection-induced 3 susceptibility to, AD, OMIM:608033;				
	NC_000002.11:g.109382226G>A NM_006267.5(RANBP2):c.5231G>A (p.Cys1744Tyr)	Not found (NE, Total AF)	1	Missense	Not previously reported
SCN1A	Associated OMIM conditions for both *SCN1A* variants below: Febrile Seizures, Familial, 3A, AD, OMIM:604403 Migraine, familial hemiplegic, 3, AD, OMIM:609634 Dravet Syndrome, AD, OMIM:607208 Epilepsy, generalized, with febrile seizures plus, Type 2, AD, OMIM:604403				
	NC_000002.11:g.166848857A>G NM_006920.6(SCN1A):c.4895T>C (p.Ile1632Thr)	Not found (A, Total AF)	1	Missense	Not previously reported
	NC_000002.11:g.166892993G>T NM_006920.6(SCN1A):c.2961C>A (p.Asp987Glu)	Not found (NE, Total AF)	1	Missense	Severe myoclonic epilepsy in infancy, LP Not provided, VUS
SCN2A	Associated OMIM conditions for the *SCN2A* variant below: Episodic ataxia type 9, AD, OMIM:618924; Developmental and epileptic encephalopathy 11, AD, OMIM:613721; Seizures benign familial infantile 3, AD, OMIM:607745;				
	NC_000002.11:g.166246035G>A NM_021007.3(SCN2A):c.5719G>A (p.Val1907Met)	Not found (NE) 0.000003989 (Total AF)	1	Missense	Not previously reported
SCN4A	Associated OMIM conditions for the *SCN4A* variant below: Hyperkalemic periodic paralysis type 2, AD, OMIM:170500; Paramyotonia congenita, AD, OMIM:168300; Myotonia congenita atypical acetazolamide-responsive, AD, OMIM:608390; Myasthenic syndrome congenital 16, AR, OMIM:614198; Hypokalemic periodic paralysis type 2, AD, OMIM:613345				
	NC_000017.10:g.62022878A>G NM_000334.4(SCN4A):c.3562T>C (p.Tyr1188His)	Not found (A) 0.000003988 (Total AF)	1	Missense	Inborn genetic diseases, VUS Not provided, VUS Hyperkalemic periodic paralysis, VUS

SCN8A	Associated OMIM conditions for the *SCN8A* variant below: Developmental and epileptic encephalopathy 13, AD, OMIM:614558 Cognitive impairment with or without cerebellar ataxia, AD, OMIM:614306 Myoclonus, familial 2, AD, OMIM:618364				
	NC_000012.11:g.52115618A>T NM_014191.4(SCN8A):c.1924A>T (p.Thr642Ser)	Not found (A, Total AF)	1	Missense	Not previously reported
SCN9A	Associated OMIM conditions for both *SCN9A* variants below: Neuropathy hereditary sensory and autonomic type IID, AR, OMIM:243000; Small fiber neuropathy, AD, OMIM:133020; Paroxysmal extreme pain disorder, OMIM:167400; Insensitivity to pain, congenital, AR, OMIM:243000; Erythermalgia primary, AD, OMIM:133020;				
	NC_000002.11:g.167055652C>T NM_002977.3(SCN9A):c.5464G>A (p.Gly1822Ser)	0.00001758 (NE) 0.000007953 (Total AF)	1	Missense	Not provided, VUS Inborn genetic diseases, VUS Neuropathy; hereditary sensory and autonomic, type 2A, VUS Generalized epilepsy with febrile seizures plus, type 7, VUS
	NC_000002.11:g.167128959T>C NM_002977.3(SCN9A):c.3268A>G (p.Met1090Val)	Not found (A) 0.00001224 (Total AF)	1	Missense	Not provided, VUS Inborn genetic diseases, VUS Neuropathy, hereditary sensory and autonomic, type 2A, VUS Generalized epilepsy with febrile seizures plus, type 7, VUS
SCN11A	Associated OMIM conditions for the SCN11A variants below: Neuropathy hereditary sensory and autonomic type VII, OMIM:615548; Episodic pain syndrome, familial 3, OMIM:615552;				
	NC_000003.11:g.38941513C>T NM_014139.3(SCN11A):c.1894G>A (p.Asp632Asn)	Not found (NE, Total AF)	1	Missense	Not previously reported
	NC_000003.11:g.38924807G>A NM_014139.3(SCN11A):c.3136C>T (p.Arg1046Trp)	Not found (A) 0.000007961 (Total AF)	1	Missense	Not previously reported
SLC2A1	Associated OMIM conditions for the *SLC2A1* variant below: Dystonia 9, AD, OMIM:601042; GLUT1 deficiency syndrome 1 infantile onset severe, AR, OMIM:606777; Stomatin-deficient cryohydrocytosis with neurologic defects, AD, OMIM:608885; GLUT1 deficiency syndrome 2, childhood onset, AD, OMIM:612126; Epilepsy, idiopathic generalized susceptibility to, AD, OMIM:614847;				
	NC_000001.10:g.43392783C>T NM_006516.4(SLC2A1):c.1408G>A (p.Gly470Arg)	Not found (A) 0.000003983 (Total AF)	1	Missense	Not provided, VUS GLUT1 deficiency syndrome 1, autosomal recessive, VUS
Systemic/ Syndromic					
CHRNA1	Associated OMIM conditions with the *CHRNA1* variant below: Myasthenic syndrome, congenital, 1A, slow-channel, AD, OMIM:601462; Myasthenic syndrome, congenital, 1B, fast-channel, AD, OMIM:608930; Multiple pterygium syndrome, lethal type, AR, OMIM:253290;				
	NC_000002.11:g.175619130G>C NM_000079.4(CHRNA1):c.357C>G (p.Asp119Glu)	Not found (NE) 0.000003985 (Total AF)	1	Missense	Not provided, VUS Lethal multiple pterygium syndrome, VUS

FLNA	Associated OMIM conditions with both *FLNA* variants below: Otopalatodigital syndrome type I, X-linked dominant; OMIM:311300; Congenital short bowel syndrome, X-linked recessive, OMIM:300048; Otopalatodigital syndrome type II, OMIM:304120; Intestinal pseudoobstruction, neuronal, X-linked recessive; OMIM:300048; Melnick-Needles syndrome, X-linked dominant, OMIM:309350; Cardiac valvular dysplasia, X-linked, OMIM:314400; FG syndrome 2, X-linked, OMIM:300321; Heterotopia, Periventricular 1, X-linked dominant OMIM:300049; Terminal osseous dysplasia, X-linked dominant, OMIM:300244; Frontometaphyseal dysplasia 1, X-linked recessive, OMIM:305620;				
	NC_000023.10:g.153588821G>C NM_001456.4(FLNA):c.3342C>G (p.Cys1114Trp)	Not found (A, Total AF)	1	Missense	Oto-palato-digital syndrome, type II, VUS Frontometaphysea dysplasia, VUS Heterotopia, periventricular, X-linked dominant, VUS Melnick-Needles syndrome, VUS
	NC_000023.10:g.153577231C>T NM_001456.4(FLNA):c.7906G>A (p.Val2636Ile)	0.00001285 (NE) 0.000005687 (Total AF)	1	Missense	Developmental delay, VUS
PHOX2B	Associated OMIM conditions with the *PHOX2B* variant below: Neuroblastoma with Hirschsprung disease, OMIM:613013; Central hypoventilation syndrome congenital with or without Hirschsprung disease, AD, OMIM:209880;				
	NC_000004.11:g.41750401C>G NM_003924.4(PHOX2B):c.227G>C (p.Ser76Thr)	0.0001976 (Hisp) 0.00003907 (Total AF)	1	Missense	Hereditary cancer-predisposing syndrome, B Not provided, VUS Congenital central hypoventilation, VUS Neuroblastoma, susceptibility to, 2, VUS Haddad syndrome, VUS
POLG	Associated OMIM conditions with the *POLG* variant below: Progressive external ophthalmoplegia with DNA deletions, AD, OMIM: 157640; Mitochondrial DNA depletion syndrome 4B (MNGIE type), AR, OMIM:613662; Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), AR, OMIM:607459; Mitochondrial DNA depletion syndrome 4A (Alpers type), AR, OMIM:203700; Progressive external ophthalmoplegia 1, AR, OMIM:258450;				
	NC_000015.9:g.89862458C>T NM_002693.3(POLG):c.3104+1G>A	0.0001202 (A) 0.00001061 (Total AF)	1	Splice donor	Progressive sclerosing poliodystrophy, LP/P Not provided, LP
TBX5	Associated OMIM conditions with both *TBX5* variant below: Holt-Oram syndrome, AD, OMIM:142900;				
	NC_000012.11:g.114841675A>C NM_000192.3(TBX5):c.29T>G (p.Leu10Arg)	Not found (Hisp, Total AF)	1	Missense	Not previously reported
	NC_000012.11:g.114793873G>C NM_000192.3(TBX5):c.1021C>G (p.Pro341Ala)	Not found (A, Total AF)	1	Missense	Cardiovascular phenotype, VUS
TSC1	Associated OMIM conditions with all *TSC1* variants below: Tuberous sclerosis-1, AD, OMIM:191100; Focal cortical dysplasia type II somatic, OMIM:607341; Lymphangioleiomyomatosis, OMIM:606690;				
	NC_000009.11:g.135772112T>A NM_000368.5(TSC1):c.3005A>T (p.Asp1002Val)	0.00002677 (NE) 0.00006454 (Total AF)	1	Missense	Hereditary cancer-predisposing syndrome, LB Not provided, LB Tuberous sclerosis 1, VUS Isolated focal cortical dysplasia type II, LB

	NC_000009.11:g.135772578C>T NM_000368.5(TSC1):c.2968G>A (p.Glu990Lys)	0.00002639 (NE) 0.00006365 (Total AF)	1	Missense	Hereditary cancer-predisposing syndrome, LB Not provided, LB Tuberous sclerosis 1, VUS Isolated focal cortical dysplasia type II, LB
	NC_000009.11:g.135781212G>A NM_000368.5(TSC1):c.1753C>T (p.Pro585Ser)	Not found (NE) 0.000003982 (Total AF)	1	Missense	Hereditary cancer-predisposing syndrome, VUS Tuberous sclerosis 1, Not provided, VUS
	NC_000009.11:g.135786914_135786916del NM_000368.5(TSC1):c.957_959del (p.Leu320del)	Not found (NE, Total AF)	1	Inframe deletion	Tuberous sclerosis 1, LB Not provided, LB/VUS Seizure, VUS Hereditary cancer-predisposing syndrome, VUS
Variants in genes previously implicated in SIDS/SUID and their associated conditions in ClinVar and OMIM. A=African/African American; AD=Autosomal Dominant; AF=Allele Frequency; AI=American Indian; AR=Autosomal Recessive; B=Benign; Hisp=Hispanic; LB=Likely Benign; LP=Likely Pathogenic; NE=Northern European; P=Pathogenic; VUS = Variant of Uncertain Significance;					

Table 4. Other Pathogenic/Likely Pathogenic Variants

Gene	Variant Information	Allele Frequency (AF) in gnomAD	Number of Cases	Molecular Consequence	Previously Reported Related Condition (ClinVar)
ALB	Associated OMIM Conditions for the *ALB* variant below: Dysalbuminemic hyperthyroxinemia, AD, OMIM:615999 Analbuminemia, AD, OMIM:616000				
	NC_000004.11:g. 74274452C>T NM_000477.7(ALB):c.412C>T (p.Arg138Ter)	0.0000155 (NE) 0.000007075 (Total AF)	1	Stop gained	Congenital analbuminemia, P Analbuminemia Bethesda, P
C12orf65/ MTRFR	Associated OMIM Conditions for the *C12orf65* variant below: Spastic paraplegia, combined oxidative phosphorylation deficiency 7, OMIM:613559				
	NC_000012.11:g.123738317_123738320dup NM_152269.5(MTRFR):c.96_99dup (p.Pro34fs)	0.00008521 (NE) 0.00003890 (Total AF)	1	Frameshift	Combined oxidative phosphorylation defect type 7 Spastic paraplegia, P Not Provided, P
DYNC1H1	Associated OMIM Conditions for the *DYNC1H1* variant below: Mental retardation 13, AD, OMIM:614563 Spinal muscular atrophy lower extremity-predominant 1, AD, OMIM:158600 Charcot-Marie-Tooth disease, axonal, type 20, AD, OMIM:614228				
	NC_000014.8:g. 102457904A>G NM_001376.5(DYNC1H1):c.2909A>G (p.Tyr970Cys)	Not found (NE, Total AF)	1	Missense	Spinal muscular atrophy, lower extremity -predominant, 1, autosomal dominant, P
GPR98/ ADGRV1	Associated OMIM Conditions for both *GPR98/ADGRV1* variants below: Febrile seizures, familial, 4, AD, OMIM:604352 Usher syndrome, type 2C, GPR98/PDZD7 digenic, AR, OMIM:605472				
	NC_000005.9:g.89986808C>T NM_032119.4(ADGRV1):c.6901C>T (p.Gln2301Ter)	0.0001091 (NE) 0.00004993 (Total AF)	1	Stop gained	Febrile seizures, familial, 4 Usher syndrome type 2C, P Usher syndrome type 2C, LP/P Rare genetic deafness, P Not provided, P
	NC_000005.9:g. 90119376C>A NM_032119.4(ADGRV1):c.16331C>A (p.Thr5444Lys)	0.0006544 (NE) 0.0003458 (Total AF)	1	Missense	Febrile seizures, familial, 4 Usher syndrome type 2C, VUS Not provided, VUS
HBA2	Associated OMIM Conditions for the *HBA2* variant below: Thalassemia alpha, OMIM:604131 Erythrocytosis 7, AD, OMIM: 617981 Heinz body anemia, AD, OMIM: 140700 Hemoglobin H disease, deletional and nondeletional, OMIM:613978				
	NC_000016.9:g.223515del NM_000517.6(HBA2):c.345del (p.Ala116fs)	0.0000447 (AA) 0.000007227 (Total AF)	1	Frameshift	Not provided, P
PIEZO2	Associated OMIM Conditions for *PIEZO2* variant below: Arthrogryposis distal with impaired proprioception and touch, AR, OMIM:617146; Arthrogryposis distal Type 3, AD, OMIM:114300 ; Arthrogryposis distal Type 5, AD, OMIM:108145 Marden-Walker syndrome, AD, OMIM:248700				
	NC_000018.9:g.10680240del NM_001378183.1(PIEZO2):c.7911del (p.Asn2638fs)	0.0000176 (NE) 0.00001195 (Total AF)	1	Frameshift deletion	Inborn genetic diseases, P
SPG7	Associated OMIM Conditions for the *SPG7* variant below: Spastic paraplegia 7, autosomal recessive, (AD/AR), OMIM:607259				

	NC_000016.9:g. 89576947T>A NM_003119.4(SPG7):c.233T>A (p.Leu78Ter)	0.0001550 (NE) 0.0003964 (Total AF)	1	Stop gained	Spastic Parapalegia 7, P

Variants in genes previously determined to be pathogenic/likely pathogenic and their associated conditions in ClinVar and OMIM.
A=African/African American; AD=Autosomal Dominant; AF=Allele Frequency; AI=American Indian; AR=Autosomal Recessive; B=Benign; Hisp=Hispanic; LB=Likely Benign; LP=Likely Pathogenic; NE=Northern European; P=Pathogenic; VUS = Variant of Uncertain Significance;



Figure 1. Methods Flowchart. Tissue samples were obtained from the NIH NeuroBioBank, Seattle Children's Hospital, and the University of Washington. They were screened for asphyxiation, and determined to be SIDS, SUID, or control samples. Samples that were determined to be cases without evidence of mechanical asphyxiation were submitted for WGS and analysis. Control VCFs were obtained from Veritas and both cases and controls were joint called for variants. The results were subjected to both gene level and variant level analysis.



Figure 2. UMAP to visualize population structure across cases and controls. Ancestry of clusters is labeled based on self-identified race as well as GrafPop results on the genotype data.



Figure 3. Gene-level Poisson test for rate of observation of variants in cases vs. controls. A total of 9764 variants filtered for allele frequency and evidence of pathogenicity were included for testing. Genes with significance at FDR < 0.05 are labeled.



Figure 4. Proportion of individuals, in each of 18 genes with a significantly higher rate of variants in cases as compared to controls, with at least one potentially pathogenic variant. Ancestry was determined by clustering in UMAP. Individuals are split by case/control and by ancestry group, with individuals of Asian ancestry not shown since only one case was of Asian ancestry. AFR = African ancestry; EUR = European ancestry. Error bars indicate 95% margin of error on proportions. A total of 9764 variants filtered for allele frequency and evidence of pathogenicity were analyzed.



Figure 5. ROS Pathway. Twenty variants in eight genes (*AAGAB, ATM, BRCA1, CFTR, COL7A1, ITGB3, LAMB3 and SMAD3*) that function in the ROS pathway were found in 21 infants who succumbed to SUID.



Figure 6. Average Age of Death by Variant Group for Infants with Single Variant. Thirty-one infants with a single cardiac gene variant died at an average of 9.9 ± 5.6 weeks of age, whereas the 13 infants that were found to have a single variant in a gene related to neurologic function died on average at 15.0 ± 7.3 weeks. The 12 infants with a single variant in a ROS pathway gene died at the average age of 15.4 ± 13.0 weeks of age. ANOVA was run in R and revealed that these differences were significant (P=0.045).